Document:

Exhibit 10.18

 

[***] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

	CONFIDENTIAL	Execution Version

 

STRATEGIC
PARTNERSHIP AGREEMENT

 

This
Strategic Partnership Agreement (the “Agreement”) by and between Oncobiologics, Inc., a Delaware
corporation with a principal place of business at 7 Clarke Drive, Cranbury, New Jersey 08512 USA (“Oncobiologics”),
and MTTR, LLC, a Delaware limited liability company, with a principal place of business at [***] (“MTTR”), is
effective as of February 15, 2018 (the “Effective Date”). Oncobiologics and MTTR are sometimes referred to herein
individually as a “Party” and collectively as the “Parties”.

 

RECITALS

 

WHEREAS, Oncobiologics
is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing, and commercializing complex biosimilar
therapeutics in immunology and oncology disease areas;

 

WHEREAS, MTTR is controlled
by a group of Consultants (as defined below) that are physicians and/or executives with professional expertise in ophthalmology,
including scientific, medical and regulatory affairs, as well as commercial operations and strategic planning;

 

WHEREAS, Oncobiologics
is developing a biosimilar product of bevacizumab; and

 

WHEREAS, the Parties
desire for Oncobiologics to engage MTTR as a consulting company to perform, through its Consultants, the Services (as defined below),
and for MTTR to provide such Services; all on the terms and conditions described herein.

 

NOW THEREFORE, in consideration
of the promises and mutual agreements contained herein, the Parties hereto, intending to be legally bound, agree as follows:

 

		1.	Definitions

 

1.1         “Actual
Deductible Costs” means the aggregate amount of the following costs incurred after the Effective Date:

 

(a)          the
aggregate amount of all costs and expenses incurred by Oncobiologics or its Affiliates for the pre-clinical or clinical Development
of Products [***], including all costs identified in Exhibit D as “Development Costs”, in each case, [***],
(“Development Costs”);

 

(b)          the
aggregate amount of all costs and expenses incurred by Oncobiologics or its Affiliates in connection with the manufacture or Commercialization
of Products [***];

 

    	1

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

(c)          the
aggregate amount of all costs and expenses incurred by Oncobiologics or its Affiliates in bringing an appropriate suit or other
action against any person or entity engaged in any existing or threatened infringement of any patent right owned or controlled
by Oncobiologics or its Affiliates that Covers the Development, Commercialization, manufacture, making, having made, use, offering
for sale, sale, having sold, importation or exportation of a Product in the Field in the Territory [***]; and

 

(d)          to
the extent Oncobiologics reasonably believes that it is required to obtain a license or similar right under any Third Party IP
to make, have made, use, offer for sale, sell, have sold, import or export any Product in the Field in the Territory, the aggregate
amount of all any royalties, milestones, upfront fees or other payments payable by Oncobiologics or its Affiliates during the Term
for such license or similar right pursuant to an agreement with a Third Party (and including, for clarity, any such licenses or
similar rights obtained by Oncobiologics prior to the Effective Date for the exercise of similar rights during the Term [***]) (each such agreement with a Third Party, a “Third Party IP Agreement”). For the purposes
of this Agreement, “Third Party IP” means any patent right that is owned or controlled by a Third Party and
to the extent it Covers the making, having made, using, offering for sale, selling, having sold, importing or exporting a Product
in the Field in the Territory.

 

Notwithstanding the
foregoing, Actual Deductible Costs shall not include any such costs, expenses or other amounts for which Oncobiologics or its Affiliates
have received prepayment or reimbursement from any Third Party, including in connection with the grant of a license or other right
with respect to Product(s) for the Field in the Territory. For clarity, any amounts excluded from the definition of Other Income
under subsections (a) – (c) of Section 1.33 shall not be Actual Deductible Costs.

 

1.2         “Adjusted
Deductible Cost” means, for purposes of the calculation of Net Profits for a Calendar Year, the cumulative Actual Deductible
Costs for a given Product that do not exceed (i) [***] percent ([***]%) of the gross revenues received by Oncobiologics or
its Affiliates in such Calendar Year, for the [***] period after First Commercial Sale of such Product, and (ii) [***] ([***]%)
of the gross revenues received by Oncobiologics or its Affiliates in such Calendar Year, for any other Calendar Year.

 

1.3         “Affiliate”
means, with respect to a Party, any entity which controls, is controlled by or is under common control with such Party. For purposes
of this definition only, “control” means the actual power, either directly or indirectly through one or more intermediaries,
to direct or cause the direction of the management and policies of such entity, whether by the ownership of fifty percent (50%)
or more of the securities entitled to be voted generally or in the election of directors of such entity, or by contract or otherwise.
For clarity, once an entity ceases to be an Affiliate of a Party, then, without any further action, such entity shall cease to
have any rights under this Agreement by reason of being an Affiliate of such Party.

 

1.4         “Anti-Corruption
Laws” means laws, regulations, or orders prohibiting the provision of a financial or other advantage for a corrupt purpose
or otherwise in connection with the improper performance of a relevant function, including without limitation, the US Foreign Corrupt
Practices Act (FCPA), and similar laws governing corruption and bribery, whether public, commercial or both, to the extent applicable.

 

    	2

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

1.5         “Applicable
Laws” means, individually and collectively, any federal, state, local, national and supra-national laws, treaties, statutes,
ordinances, rules and regulations, that are in effect from time to time during the Term and applicable to a particular activity
hereunder.

 

1.6         “Approved
Indication(s)” means any Indication for which a Product has received Regulatory Approval (whether in the United States
or in any other country in the Territory).

 

1.7         “Biosimilar”
means a biological product that: [***] .

 

1.8         “BPCI
Act” means the Biologics Price Competition and Innovation Act of 2009 within the Patient Protection and Affordable Care
Act, as set forth in Section 351(k) of the PHS Act (42 U.S.C. 262), which was signed into law in the United States in March
2010, and as may be subsequently amended.

 

1.9         “Business
Day” means a day other than Saturday, Sunday or any day that banks in the U.S. are required or permitted to be closed.

 

1.10      “Calendar
Quarter” means the period beginning on the Effective Date and ending on the last day of the calendar quarter in which
the Effective Date falls, and thereafter each successive period of three (3) consecutive calendar months ending on March 31, June
30, September 30 and December 31; provided, that, the final Calendar Quarter shall end on the last day of the Term.

 

1.11       “Calendar
Year” means the period beginning on the Effective Date and ending on December 31 of the calendar year in which the Effective
Date falls, and thereafter each successive period of twelve (12) months commencing on January 1 and ending on December 31; provided,
that, the final Calendar Year shall end on the last day of the Term.

 

1.12       “Change
of Control” means, with respect to Oncobiologics: (a) the sale of all or substantially all of Oncobiologics’s assets
or business; (b) a merger, reorganization or consolidation involving Oncobiologics in which the voting securities of Oncobiologics
outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving
entity immediately after such merger, reorganization or consolidation; or (c) a person or entity, or group of persons or entities,
acting in concert acquire more than fifty percent (50%) of the voting equity securities or management control of Oncobiologics.

 

1.13       “Cost
of Goods Sold” or “COGS” means the fully burdened costs incurred by Oncobiologics or its Affiliates,
in U.S. Dollars (as defined by Oncobiologics’s consistent application of GAAP), in manufacturing or having manufactured Products.

 

    	3

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

1.14       “Commercially
Reasonable Efforts” means, with respect to a Party’s obligations under this Agreement, the carrying out of such
obligations with a level of efforts and resources consistent with the commercially reasonable practices of a similarly situated
company in the pharmaceutical industry for developing or seeking Regulatory Approval of a similarly situated branded pharmaceutical
product as the Product at a similar stage of development, taking into account efficacy, safety, patent and regulatory exclusivity,
anticipated or approved labeling, present and future market potential, competitive market conditions, the profitability of the
product in light of pricing and reimbursement issues, and all other relevant factors.

 

1.15       “Commercialization”
or “Commercialize” means all activities directed to marketing, promotion, distribution, detailing or selling
a Product (including supply chain, importing and exporting activities in connection therewith).

 

1.16       “Confidential
Information” of a Party means any and all Information of a Party (the “Disclosing Party”) that is
disclosed to the other Party (the “Receiving Party”) related to activities conducted pursuant to this Agreement,
whether in oral, written, graphic, or electronic form, provided that any information that is disclosed in writing shall be marked
as “Confidential” and any information not disclosed in writing shall be designated by the Disclosing Party as confidential
at the time of its initial disclosure and reduced to a written summary by the Disclosing Party that is marked in a manner to indicate
its confidential nature and delivered to the Receiving Party within [***] after its initial disclosure (provided, however, that
such requirement to summarize in writing non-written disclosures shall not apply to information that pertains to the Product that
the Receiving Party knew, or reasonably should have known, was the Confidential Information of the Disclosing Party). In addition
all Information disclosed by a Party pursuant to the Confidentiality Agreement between the Parties dated February 2, 2018 (the
“Confidentiality Agreement”) shall be deemed to be Confidential Information of such Party disclosed hereunder;
provided, however, that any use or disclosure of any such Information that is authorized under Article 13 shall not be restricted
by, or be deemed a violation of, the Confidentiality Agreement.

 

1.17       “Consultant”
(or, collectively, “Consultants”) means each of (a) [***], an individual and citizen of the U.S. residing, as
of the Effective Date, in the state of [***] (“[***]”); (b) [***], an individual and citizen of the U.S. residing,
as of the Effective Date, in the state of [***] (“[***]”); (c) Mr. Terry Dagnon, an individual and citizen of
the U.S. residing, as of the Effective Date, in the state of [***] (“Mr. Dagnon”); and (d) [***], an individual
and citizen of the U.S. residing, as of the Effective Date, in the state of [***] (“[***]”).

 

1.18       “Cover,”
“Covering” or “Covered” means, with respect to any Product, that the manufacture, use, offer for sale,
sale, import or export of such Product in the Field in a particular country in the Territory by a party who has not been granted
a license or similar right under patent rights owned or controlled by another party would infringe a valid claim of such other
party’s patent rights.

 

1.19       “Development”
(with a correlative meaning for “Develop” and “Developing”) means all activities relating
to preclinical and clinical trials, toxicology testing, statistical analysis, publication and presentation of study results and
reporting, preparation and submission of applications for obtaining and maintaining Regulatory Approval of Products.

 

    	4

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

1.20       “FDA”
means the United States Food and Drug Administration or any successor entity thereto.

 

1.21       “Field”
means the treatment, prevention or cure of any ophthalmic indication, including wet macular degeneration (“Wet AMD”),
diabetic macular edema (“DME”) or diabetic retinopathy (“DR”) (together with retinal vein
occlusions, myopic choroidal neovascularization and all other ophthalmic indication, collectively, “Indications”).

 

1.22       “First
Commercial Sale” means, with respect to each country in the Territory, the first sale for end use or consumption of the
Product in such country in the Territory after Marketing Approval has been granted in such country in the Territory.

 

1.23       “GAAP”
means the then-current generally accepted accounting principles in the United States as established by the Financial Accounting
Standards Board or any successor entity or other entity generally recognized as having the right to establish such principles in
the United States, in each case consistently applied.

 

1.24       “Governmental
Authority” means any multi-national, national, federal, state, local, municipal, provincial or other governmental authority
of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission,
council, court or other tribunal).

 

1.25       “IND”
means an Investigational New Drug application filed with the FDA, or an equivalent filing outside of the U.S.

 

1.26       “Information”
means any data, results, technology, business or financial information or information of any type whatsoever, in any tangible or
intangible form, including know-how, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications,
formulae, software, algorithms, marketing reports, expertise, technology, test data (including pharmacological, biological, chemical,
biochemical, clinical test data and data resulting from non-clinical studies), CMC information, stability data or other study data
and procedures.

 

1.27       [***].

 

1.28       [***].

 

1.29       “Marketing
Authorization Application” or “MAA” means an application to the appropriate Regulatory Authority for
approval to market a Product in any particular jurisdiction and all amendments and supplements thereto.

 

1.30       “Marketing
Approval” means an approval for a Product from a Regulatory Authority necessary for the distribution, marketing and sale
of such Product, including where necessary to initiate marketing and sales, pricing and reimbursement approval(s).

 

    	5

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

1.31       “Net
Profits” means, with respect to a given Calendar Year, the Other Income and Net Revenue received by Oncobiologics and
its Affiliates in the Field in the Territory, minus Adjusted Deductible Costs, accounted for in accordance with Oncobiologics’s
standard accounting practices consistent with GAAP. Any Actual Deductible Costs that are not accounted for in the definition of
“Net Profits” due to the limitations set forth in the definition of “Adjusted Deductible Costs”,
below, may be carried forward to the calculation of Net Profits in subsequent Calendar Years until such Actual Deductible Costs
have been fully offset. [***]. Additionally, in calculating Net Profits with respect to sales of Products to Third Parties in the
Field in the Territory by a Third Party sublicensee of Oncobiologics only the cash consideration received by the Oncobiologics
or its Affiliates in connection with such sale from such Third Party sublicensee will be included in the calculation of Net Revenues,
provided that no other material consideration is received by Oncobiologics in connection therewith.

 

1.32       “Net
Revenues” means, with respect to any Product, the gross sales price of such Product sold by Oncobiologics or its Affiliates
(the “Selling Party”) to Third Parties, less:

 

 [***]

 

Net Revenues will be determined
in accordance with GAAP, consistently applied throughout the organization and across all products of the Selling Party whose sales
of Products are giving rise to Net Revenues.

 

[***]

 

Where a Product is sold in combination
with other pharmaceutical products, diagnostic products, or active ingredients (collectively, “Combination Components”)
the Net Revenues applicable to such transaction shall be calculated by multiplying the total Net Revenues of such combined product
by the fraction A/(A+B), where A is the actual price of the Product in the same formulation and dosage amount or quantities in
the applicable country during the applicable quarter if sold separately, and B is the sum of the actual prices of all Combination
Components with which the Product is combined, in the same formulation and dosage amount or quantities in the applicable country
during the applicable quarter if sold separately. If A or B cannot be determined because values for the Product or Combination
Components with which the Product is combined are not available separately in a particular country, then [***].

 

Sales of Product(s) between or
among Oncobiologics and its Affiliates shall be excluded from the computation of Net Revenues and no payments shall be payable
on such sales except where such Affiliates are end users.

 

    	6

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

1.33       “Other
Income” means any consideration received by Oncobiologics or its Affiliates from a Third Party that is attributable to
Product(s) for the Field in the Territory, including any consideration received in connection with the grant of a license or other
right with respect to Product(s) for the Field in the Territory, including the grant of an option to obtain such license or other
right, but excluding in all cases: (a) payments received from such Third Party for the purposes of funding and/or reimbursing expenses
incurred by Oncobiologics or any of its Affiliates for [***] research and development activities related to Products in the Field
in the Territory, (b) payments and reimbursements by such Third Party of patent costs incurred by Oncobiologics or its Affiliates
in connection with Products in the Field in the Territory, (c) payments received from such Third Party for the supply of Products
by Oncobiologics or its Affiliates (to the extent not in excess of Oncobiologics’s COGS for such Products), and (d) payments
made by such Third Party as consideration for the issuance of equity or debt securities of Oncobiologics or its Affiliates at fair
market value (excluding amounts in excess of the fair market value of such securities).

 

1.34       “PDUFA
Fees” means any fees owed to the FDA pursuant to the Prescription Drug User Fee Act.

 

1.35       “Phase 3
Clinical Study” means a human clinical trial that would satisfy the requirements for a Phase 3 study as defined
in 21 CFR § 312.21(c) (or any amended or successor regulations), regardless of where such clinical trial is conducted.

 

1.36       “Pilot
Study” means a human clinical experience study (as defined in FDA guidance) of a Product for use in the Field in the
Territory, which study shall initially be designed for [***].

 

1.37       “Pivotal
Study” means: (a) a Phase 3 Clinical Study; or (b) any other human clinical study that the applicable
Regulatory Authority has agreed is sufficient to form the primary basis of an efficacy claim in an MAA submission, including any
such study that is determined to have become pivotal after its commencement, in each case of (a) and (b), which clinical study
shall initially be designed for approximately [***].

 

1.38       “Primary
End Point” means the primary end points set forth in Exhibit F attached hereto.

 

1.39       “Product”
means any Biosimilar of bevacizumab controlled by Oncobiologics, as such compound shall be developed by the Parties under this
Agreement (including all pharmaceutical products and formulations thereof), sold alone or in combination with one or more other
therapeutically active ingredients.

 

1.40       “Regulatory
Approval” means an approval, clearance or authorization for the Product from a Regulatory Authority necessary for the
research, Development, manufacture, distribution, pricing, reimbursement, marketing or sale of the Product, including any Marketing
Approval.

 

1.41       “Regulatory
Authority(ies)” means any Governmental Authority or other authority responsible for granting Regulatory Approvals for
the Product, including the FDA and any corresponding national or regional regulatory authorities.

 

1.42       “Regulatory
Exclusivity” means, with respect to a Product and country, the rights conferred by any Regulatory Authority in such country
with respect to such Product, including the rights conferred in the United States under 42 U.S.C. §262 or comparable rights
outside of the United States.

 

    	7

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

1.43       “Successful
First FDA Interaction” means written approval by the FDA (after discussions with the FDA) to conduct a Pilot Study requiring
no more than [***], and written guidance from the FDA that a Pivotal Study will not require more than [***].

 

1.44       “Territory”
means all countries or territories in the world, excluding Mexico.

 

1.45       “Third
Party” means any Person that is not a Party, or an Affiliate of a Party.

 

1.46       “United
States” or “U.S.” means the United States of America and its territories and possessions.

 

2.            Performance
of Services; Records; Deliverables

 

2.1         Services.
The Parties agree that, among other things, MTTR will provide to Oncobiologics strategic advice for the Development, seeking and
obtaining Regulatory Approval and Commercialization, of the Product in the Field in the Territory as agreed upon in writing by
the Parties during the Term, including such services set forth in Exhibit A, attached hereto (the “Services”;
the description and/or list of such Services, the “Services Schedule”). The Services Schedule can only be amended
in a writing signed by the Parties. MTTR agrees to exercise the professionalism consistent with industry standard for the performance
of similar services and utilize its collective expertise and creative talents in performing the Services. In addition to any JSC
(as defined below) meetings agreed upon by the Parties, MTTR agrees to make the Consultants reasonably available to meet with Oncobiologics
(in person or by teleconference), as reasonably requested by Oncobiologics from time to time, consistent with such Consultant’s
time commitment set forth in Section 2.2(b). This Agreement will take precedence over any contrary or inconsistent terms or conditions
appearing in or referred to in any exhibit, unless the exhibit expressly refers to the Parties’ intent to alter the terms
of this Agreement with respect to such exhibit.

 

2.2         Expertise;
Time Commitments; Replacement.

 

(a)          The
Consultants have the respective expertise ascribed to their names in Exhibit B. MTTR agrees to inform Oncobiologics in the
event that any of the Consultants is no longer qualified to represent itself as an expert in accordance with Exhibit B.

 

(b)          MTTR
shall ensure that each Consultant commits to dedicate a percentage of his time on a full-time equivalent basis, which shall constitute
[***] hours (“FTE”), to the performance of Services under this Agreement, in accordance with the respective
Development Stage (as defined below) of the Product and determined on a Calendar Quarter basis, pursuant to the schedule set forth
in Exhibit B.

 

    	8

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

(c)          MTTR
shall not replace [***] with any person during the Term; provided that, if [***] dies, becomes incapacitated or voluntarily resigns
from employment at MTTR (through no fault of MTTR), MTTR shall have the right to suggest a replacement consultant by notifying
Oncobiologics promptly (but in any event no later than [***]) after the occurrence of such trigger event; provided that, Oncobiologics
may withhold consent to such replacement consultant, in Oncobiologics’s sole discretion; provided further, that if Oncobiologics
does not approve of such replacement consultant, then this Agreement will terminate in its entirety in accordance with Section
15.5(a).

 

(d)          MTTR
shall have the right to replace each of [***] with another person with similar qualifications, solely with the prior written approval
of Oncobiologics ([***]). If Oncobiologics does not approve any such replacement consultant for [***], then Oncobiologics shall
provide its basis for non-approval. Notwithstanding the foregoing, if Oncobiologics does not approve of such replacement consultant
after good faith consideration, then this Agreement will terminate with respect to such Consultant in accordance with Section 15.5(b).

 

(e)          Upon
any approval of a replacement consultant in accordance with subsection (c) or (d) above, any and all references in this Agreement
to the applicable replaced Consultant shall be deemed to refer to the replacement consultant, without any further modification
of the terms and conditions of this Agreement, unless otherwise agreed by the Parties in writing.

 

2.3         Records.

 

(a)          MTTR
shall ensure that the Consultants shall maintain complete and accurate records of the status and progress of the Services, and
all materials, information, data or other know-how generated, authored, conceived or reduced to practice by the Consultants in
the course of performing the Services, in accordance with Applicable Law (collectively, the “Records”). MTTR
shall maintain the Records in sufficient detail to properly reflect, in a reasonable manner, all significant Services performed
and the results of such Services, at a level of detail appropriate for patent and regulatory purposes.

 

(b)          Upon
expiration or termination of this Agreement, and upon such other times as requested by Oncobiologics during the Term, MTTR shall
(i) provide to Oncobiologics copies of the Records and (ii) allow Oncobiologics to access, review and copy the Records (including
access to relevant databases). At no time shall MTTR dispose of any Records without first giving Oncobiologics [***] prior written
notice of its intent to dispose such Records.

 

2.4         Deliverables.
MTTR will deliver to Oncobiologics all Records, reasonable descriptions of Inventions, reports, documentation, data, information
or materials as set forth in the Services Schedule or otherwise generated in the course of performing the Services (collectively,
“Deliverables”), within [***] of the completion of the Services, or as otherwise set forth in the Services Schedule.
Any failure by MTTR to deliver such Deliverables to Oncobiologics within such time period [***]. The Parties acknowledge that (a)
all information regarding regulatory pathway and strategy with respect to the Product for the Field in the Territory disclosed
by MTTR to Oncobiologics (“MTTR Regulatory Strategy”) shall be MTTR’s Confidential Information (which,
for avoidance of doubt, may be used by Oncobiologics in accordance with the license grant to Oncobiologics under Section 10.3 and
the non-use and non-confidentiality obligations under Article 13) and (b) all Deliverables, other than MTTR Regulatory Strategy,
shall be deemed Oncobiologics’s Confidential Information.

 

    	9

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

3.            Governance

 

3.1         JSC
Formation and Role. The Parties hereby establish a joint steering committee (the “Joint Steering Committee”
or “JSC”). The JSC shall have the following responsibilities:

 

(a)          to
serve as a forum for the Consultants to discuss and share updates with respect to their performance of the Services, including
strategies for the Development and/or Commercialization of the Product (including presentation of the then-current Development
Plan and/or Commercialization Plan), regulatory updates and marketing materials;

 

(b)          to
serve as a forum for Oncobiologics to discuss and share updates with respect to its Development, regulatory and Commercialization
efforts under this Agreement and/or to review and approve any material updates to the Development Plan, the Commercialization Plan
(including any material updates thereto), drafts of regulatory filings or communications and marketing materials, with respect
to Products for the Field in the Territory;

 

(c)          to
discuss the Development of Products for use in the Field in the Territory in the First Indication, Second Indication and any Additional
Indications, including the order and prioritization of such Development activities in the respective Indications in accordance
with Section 4.3(a);

 

(d)          to
discuss, coordinate and share updates and information with respect to the Parties’ respective interactions with Regulatory
Authorities, with respect to Products for the Field in the Territory; and

 

(e)          to
perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement
or as agreed by the Parties in writing.

 

3.2         Members.
The JSC shall be comprised of (a) at least two (2) of the Consultants (provided that, at all times after commencement of Development
Stage 2 with respect to a Product in the Field in the Territory, all four (4) Consultants shall be present at the JSC); and (b)
four (4) representatives from Oncobiologics (with each representative of Oncobiologics being an officer, employee or consultant
of Oncobiologics or its Affiliate having sufficient seniority to make decisions arising within the scope of the JSC’s responsibilities).
The initial members of the JSC from Oncobiologics and MTTR are as set forth on Exhibit G attached hereto; provided that,
Oncobiologics may replace its representatives with an officer, employee or consultant of Oncobiologics or its Affiliates at any
time upon written notice to MTTR. For purposes of any particular JSC meeting, MTTR may substitute an “Initial JSC Member”
with an “Initial Alternate JSC Member”, each as described in Exhibit G attached hereto. The JSC may change its
size from time to time by mutual consent of the Parties. Oncobiologics shall appoint one (1) of its representatives to act as the
chairperson of the JSC. The role of the chairperson shall be to convene and preside at the JSC meeting, to ensure the circulation
of meeting agendas in advance of JSC meetings and to prepare meeting minutes and circulate to all of the JSC members such minutes
that reflect all material decisions made at such meetings.

 

    	10

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

3.3         Meetings.
The JSC shall meet at least once per calendar month during the Term, unless the Parties mutually agree in writing to a different
frequency for such meetings. Either Party may also call a special meeting of the JSC (by videoconference or teleconference) upon
at least [***] prior written notice to the other Party in the event such Party reasonably believes that a significant matter must
be addressed prior to the next regularly scheduled meeting. The JSC may meet in person, by videoconference or by teleconference
(provided, however, that, unless the Parties otherwise mutually agree, at least [***] JSC meetings per [***] shall be in
person until commencement of Development Stage 3 with respect to a Product in the Field in the Territory, after which at least
[***] JSC meeting per [***] shall be in person, and MTTR shall have the right to select the location of the first in-person meeting
(and, thereafter, the location shall be selected by the Parties on an alternating basis). [***]. The participation at JSC meetings
by the Consultants, in accordance with Section 3.2(a), shall be mandatory. Oncobiologics may have additional employee representatives
and consultants of Oncobiologics attend JSC meetings as non-voting participants, including one employee to act as secretary of
the meeting. MTTR may have additional employee representatives and consultants of MTTR attend JSC meetings as non-voting participants.
All JSC meetings shall be conducted in English and all communications under this Agreement shall be in English. The chairperson
shall send draft meeting minutes to each representative of the JSC for review and approval within [***] after the applicable meeting.
Such minutes shall be deemed approved when signed by the chairperson from Oncobiologics and a JSC member from MTTR; such sign off
should not be delayed and be provided within [***] after receipt thereof unless one or more JSC representatives object to the accuracy
of such minutes within said [***] period.

 

3.4         Decision
Making. The JSC shall be primarily a forum for information exchange and discussion; provided that, to the extent that any decisions
need to be made pursuant to this Agreement, the JSC shall strive to seek consensus in its actions and decision making process,
with each Party having collectively one (1) vote in all decisions. If after reasonable discussion and good faith consideration
of each Party’s view on a particular matter before the JSC, the representatives of the Parties cannot reach an agreement
as to such matter within the course of such JSC meeting, then, and subject to Section 3.5, Oncobiologics shall have the final decision-making
authority with respect to such matter, including with respect to matters regarding the Development, manufacture, seeking Regulatory
Approval or Commercialization of Products under this Agreement; [***].

 

3.5         Limitation
of JSC Authority. The JSC shall only have the powers expressly assigned to it in this Article 3 and elsewhere in this Agreement
and shall not have the authority to: (a) modify or amend the terms and conditions of this Agreement (including any material alteration
to the terms of the Services or time commitments of any Consultant); (b) waive or determine either Party’s compliance with
the terms and conditions of under this Agreement; or (c) decide any issue in a manner that would conflict with the express terms
and conditions of this Agreement.

 

    	11

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

4.            Development
Program

 

4.1         Conduct
of Development Activities. Except as expressly set forth in Exhibit A or otherwise in this Agreement with respect to
Development-related Services to be conducted by MTTR, Oncobiologics shall have the sole right and responsibility, at its sole cost
and expense, in each case in accordance with the Development Plan, for the conduct of all Development activities applicable to
Products in the Field in the Territory. At all times during the Term, MTTR shall, through the Consultants, provide Services to
Oncobiologics with respect to the Development of Products in the Field for all Indications for which Oncobiologics intends to pursue
Regulatory Approval in the Territory.

 

4.2         Preparation
of Development Plans. MTTR will prepare the non-clinical safety and clinical development plan for the Development of Products
in the Field in the Territory (which plan shall include, for clarity, any MTTR Regulatory Strategy existing as of such date with
respect to the Development of such Products in the Field in the Territory) (collectively, the “Development Plan”),
including any updates thereto, in accordance with this Section 4.2. The Development Plan shall reflect at least the use of Commercially
Reasonable Efforts to obtain Regulatory Approval of the Product in the Field for [***]. The initial Development timeline is attached
hereto as Exhibit E. Subject to the remainder of this Section 4.2, MTTR shall submit any non-material updates to the Development
Plan to Oncobiologics for review and approval by Oncobiologics. MTTR will incorporate all feedback provided by Oncobiologics (after
any reasonable discussion requested by MTTR) with respect to the Development Plan, and the Parties will communicate, cooperate
and share information with each other on an ongoing basis during the Term in order to keep each other informed as to the Development
of the Product and enable MTTR to revise the Development Plan to reflect the then-current plans for Oncobiologics’s Development
of Products in the Field in the Territory. MTTR shall provide any material updates to the Development Plan to the JSC at least
[***] for review and approval by the JSC in accordance with Article 3. The Development Plan and updates thereto shall contain a
reasonably detailed summary of (a) all major Development activities (including all clinical studies) conducted under this Agreement
since the last Development Plan and (b) all major Development activities proposed to be conducted under this Agreement, including
the anticipated timelines for achieving such activities.

 

4.3         Initial
Development Activities.

 

(a)          Oncobiologics
will initially Develop and submit for Regulatory Approval Products in the following Indications: (i) intravitreal
injection of Product for the treatment of Wet AMD (the “First Indication”), and (ii) intravitreal
injection of Product for the treatment of DME (the “Second Indication”). The Parties shall jointly
discuss and evaluate, through the JSC, the Development of Products for treatment of Indications other than the First
Indication and Second Indication (each, an “Additional Indication”). For clarity, the terms “First
Indication”, “Second Indication” and “Additional Indications” may not track the actual temporal
order of Development of the Product (i.e., Oncobiologics may Develop the Product in the Field for the Second
Indication or an Additional Indication prior to the First Indication), as discussed by the Parties through the JSC and
without limiting Section 4.3(b).

 

    	12

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

(b)          Oncobiologics
will use Commercially Reasonable Efforts to Develop and seek Marketing Approval of a Product in the Field for the First Indication,
the Second Indication, or an Additional Indication (whichever Indication is the lead Indication at such time). Oncobiologics will
not delay filing for Marketing Approval in the U.S. of a Product in the Field for the lead Indication by more than one (1) Calendar
Quarter as a result of insufficient funding of the program. For clarity, in the event that Development Costs incurred specifically
for (i) conducting the Pilot Study and Pivotal Study (but excluding costs incurred in manufacturing and/or supplying Products for
use in such studies), and (ii) obtaining Regulatory Approval of Products in the Field in the U.S. (but excluding any PDUFA Fees
and all other Development or Commercialization costs incurred by Oncobiologics) either exceed or are reasonably likely to exceed
[***] U.S. Dollars ($[***]) ([***]), then Oncobiologics termination of the Development of Products shall not be considered a failure
to use Commercially Reasonable Efforts.

 

4.4         Development
Stages. The development stages for Development of the Products under this Agreement shall be as set forth below (each, a “Development
Stage”).

 

(a)          Development
Stage 1A: commences on the Effective Date and ends upon the first Successful First FDA Interaction;

 

(b)          Development
Stage 1B: commences upon the first Successful First FDA Interaction and ends upon the first completion (i.e., last patient
completion of follow-up) of a Pilot Study;

 

(c)          Development
Stage 2: commences upon the first completion of a Pilot Study and ends upon the first achievement of the Primary End Point
in a Pivotal Study;

 

(d)          Development
Stage 3: commences upon the first achievement of the Primary End Point in a Pivotal Study and ends upon the First Commercial
Sale of a Product for use in any Approved Indication in the U.S.; and

 

(e)          Development
Stage 4: commences upon the First Commercial Sale of a Product for use in any Approved Indication in the U.S.

 

5.            Exclusivity;
ROFN; Limitations

 

5.1         Exclusivity.
During the Term, MTTR shall cause each Consultant not to work for, assist or enable in any way, directly or indirectly, any Third
Party with respect to the development or commercialization of any Biosimilar of bevacizumab in the Field; so long as Oncobiologics
is using Commercially Reasonable Efforts to Develop and/or Commercialize a Product in the Field in the Territory and making all
undisputed payments owed to MTTR in connection therewith, in accordance with Article 9. MTTR shall ensure that each Consultant
acknowledges and abides by the obligations of exclusivity owed to Oncobiologics pursuant to this Section 5.1.

 

5.2         Right
of First Negotiation. [***]

 

    	13

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

5.3         Limitations.

 

(a)          Except
as expressly set forth in Section 5.2, Oncobiologics reserves the right to engage other Third Party contractors to perform any
of its Development, manufacturing, regulatory or Commercialization activities under this Agreement (“Oncobiologics Service
Providers”), subject to binding such Third Party contractor to confidentiality and non-use restrictions that are consistent
with the provisions of Article 13 with respect to any Confidential Information of MTTR disclosed to such Third Party contractor.
Oncobiologics shall permit Oncobiologics Service Providers to disclose Confidential Information of Oncobiologics to MTTR for the
sole purpose of MTTR performing its obligations under this Agreement, including the performance of Services, and shall, at MTTR’s
request, promptly inform such Third Party contractor of such permission. Notwithstanding anything to the contrary herein, with
respect to any such Confidential Information of Oncobiologics disclosed to MTTR by an Oncobiologics Service Provider, Oncobiologics
shall be deemed the “Disclosing Party” of such Confidential Information and the provisions of Article 13 shall apply
with equal force and effect to protect the confidentiality, non-use and non-disclosure of such Confidential Information by MTTR.
Subject to the terms and conditions of this Agreement, MTTR shall have the right to discuss with any Oncobiologics Service Provider
the performance of any of its obligations under this Agreement but not to engage or solicit any Oncobiologics Service Provider
to work directly for MTTR to perform such obligations without obtaining prior written consent from Oncobiologics (which consent
may not be unreasonably withheld, conditioned or delayed). For clarity, as long as MTTR is complying with its obligations under
this Agreement, Oncobiologics shall not prohibit any Oncobiologics Service Provider from working with MTTR pursuant to the immediately
preceding sentence. For avoidance of doubt, MTTR may discuss, engage or solicit any Oncobiologics Service Provider for the performance
of any activities outside the scope of this Agreement that are not in violation of MTTR’s obligations under Section 5.1.
Upon termination or expiration of this Agreement, MTTR shall not require Oncobiologics’s approval in order to work with any
Oncobiologics Service Provider.

 

(b)          Subject
to Section 5.1, MTTR and each Consultant reserves the right to perform services for other persons, provided that the performance
of such services do not conflict or interfere with the Services or MTTR’s obligations under this Agreement.

 

6.            Regulatory
Responsibilities

 

6.1         Regulatory
Activities. Except as expressly set forth in Exhibit A or otherwise in this Agreement with respect to regulatory-related
Services to be conducted by MTTR, Oncobiologics will have the sole right and responsibility, at its sole cost and expense, for
all regulatory activities with respect to Products in the Field in the Territory, and Oncobiologics shall have final decision-making
authority with respect thereto, taking into good faith consideration MTTR’s perspective as provided through the JSC and provided
that Oncobiologics shall exercise such final decision-making authority in a manner that does not delay, and is consistent with
the exercise of Commercially Reasonable Efforts with respect to, the conduct of regulatory activities with respect to Products
in the Field in the Territory.

 

    	14

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

6.2         Responsibility
for Regulatory Filings. Oncobiologics shall have the sole right and responsibility, at its sole expense, to prepare, file,
prosecute and maintain all regulatory filings for Products in the Territory in Oncobiologics’s own name; provided that, MTTR
shall provide such regulatory-related Services as set forth in Exhibit A, including providing Oncobiologics with drafts
of all regulatory filings as provided therein within a reasonable time prior to submission for Oncobiologics’s review, comment
and approval, and timely incorporating any feedback provided by Oncobiologics with respect to such regulatory filings. The Parties
will communicate, cooperate and share information with each other on an ongoing basis during the Term in order to enable MTTR to
prepare and update all applicable regulatory filings.

 

6.3         Interactions
with Regulatory Authorities. Oncobiologics will oversee, monitor and manage all regulatory interactions and communications
with Regulatory Authorities with respect to Products in the Territory; provided that, MTTR shall assist Oncobiologics as reasonably
requested by Oncobiologics in drafting (including any amendments or revisions to such drafts) or responding to any such regulatory
communications and providing such other regulatory-related Services as set forth in Exhibit A. As between the Parties, Oncobiologics
shall be responsible for all reporting to Regulatory Authorities with respect to any adverse events occurring with respect to any
Product in the Field in the Territory, in accordance with Applicable Law. MTTR shall, through the JSC, keep Oncobiologics reasonably
informed of regulatory developments related to Products in the Field in the Territory for which MTTR is responsible pursuant to
this Agreement and shall notify Oncobiologics in writing of any decision by any Regulatory Authority in the Territory regarding
Products in the Field of which it is aware. Oncobiologics shall keep MTTR reasonably informed of regulatory developments and regulatory
activities conducted by or on behalf of Oncobiologics with respect to the Product (in and outside the Field) that are relevant
to the Field, including with respect to the biosimilar approval process and the biosimilar patent dance for the Product, and shall
notify MTTR in writing of any decision by any Regulatory Authority in the Territory regarding Products that is relevant to the
Field of which it is aware.

 

6.4         Regulatory
Meetings. Oncobiologics shall provide MTTR with at least [***] prior written notice (or, to the extent such meeting or discussion
is scheduled in less than [***], immediate notice) of any material meeting or discussion with any Regulatory Authority in the Territory
related to Products in the Field. One (1) or more of the Consultants shall attend such meetings; provided that, with respect to
meetings for which Oncobiologics has given less than [***] prior written notice, the Consultants shall, upon Oncobiologics’s
request, attend such meeting by teleconference if in-person attendance is not practicable. Oncobiologics shall reimburse Consultants
for reasonable, documented travel, meal and lodging costs for such attendance to the extent in accordance with the MTTR Travel
Policy in Exhibit H attached hereto.

 

6.5         Remedial
Actions. Each Party shall notify the other immediately, and promptly confirm such notice in writing, if it obtains information
indicating that any Product may be subject to any recall, corrective action or other regulatory action by any Governmental Authority
or Regulatory Authority (a “Remedial Action”). The Parties shall assist each other in gathering and evaluating
such information as is necessary to determine the necessity of conducting a Remedial Action. Oncobiologics shall have sole discretion
with respect to any matters relating to any Remedial Action in the Territory, including the decision to commence such Remedial
Action and the control over such Remedial Action. The cost and expenses of any Remedial Action in the Territory shall be borne
solely by Oncobiologics.

 

    	15

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

7.           Commercialization

 

7.1         Responsibility
for Commercialization of Products. Except as expressly set forth in Exhibit A or otherwise in this Agreement with respect
to Commercialization-related Services to be conducted by MTTR, Oncobiologics will have the sole right and responsibility for, and
final decision-making authority with respect to, the Commercialization of Products in the Field in the Territory, including (a)
the conduct of all pre-marketing, marketing, promotion, sales, distribution, import and export activities (including the securing
of reimbursement, sales and marketing and any post-marketing trials or databases and post-marketing safety surveillance); (b) the
submission of applications for reimbursement with respect to any Product in any country in the Territory; (c) the identification
and registration of all tradenames for any Product in the Field in the Territory; (d) the out-licensing of intellectual property
owned or controlled by Oncobiologics that Covers any Product in the Field in the Territory; and (e) the booking of all sales of
Products in the Field in the Territory, in each case in accordance with the Commercialization Plan. During the Term, MTTR shall,
through the Consultants, provide Services to Oncobiologics with respect to the Commercialization of Products in the Field in the
Territory for all Approved Indications. Any promotion of the Product by any Active HCP shall be subject to the prior approval of
Oncobiologics. [***].

 

7.2         Preparation
of Commercialization Plan. MTTR will prepare the plan for the Commercialization of each Product in the Field in the Territory
(“Commercialization Plan”) and any updates thereto, in accordance with this Section 7.2. MTTR shall submit the
initial Commercialization Plan to the JSC for review and approval by the JSC, no later than [***] prior to the expected date of
First Commercial Sale of such Product. MTTR will incorporate all feedback provided by Oncobiologics (after any reasonable discussion
requested by MTTR) with respect to such Commercialization Plan, and the Parties will communicate, cooperate and share information
with each other on an ongoing basis through the Term to keep each other informed as to the Commercialization of the Product and
in order to enable MTTR to revise the Commercialization Plan to reflect Oncobiologics’s then-current plans for Commercialization
of Products in the Field in the Territory. The Commercialization Plan shall reflect at least the use of Commercially Reasonable
Efforts to market and sell the Product in the Field [***]. MTTR shall provide any material updates to the Commercialization Plan
to the JSC at least [***] each [***] for review and approval by the JSC in accordance with Article 3. The Commercialization Plan
and updates thereto shall contain a reasonably detailed summary of (a) all major Commercialization activities conducted with respect
to Products in the Field in the Territory since the last Commercialization Plan and (b) and all major Commercialization activities
proposed to be conducted with respect to Products in the Feld in the Territory, including the anticipated timelines for achieving
such activities. Subject to Section 4.3(b), Oncobiologics will use Commercially Reasonable Efforts to execute the Commercialization
Plan and maximize sales of Products for the Field in the Territory.

 

    	16

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

8.            Manufacturing

 

8.1         Responsibility.
Oncobiologics will have the sole right and responsibility, at its sole cost and expense, to manufacture clinical and commercial
supply of Products to support the Development and Commercialization of the Products for the Field in the Territory, and shall have
final decision-making authority with respect thereto, taking into good faith consideration MTTR’s perspective as provided
through the JSC and provided that Oncobiologics shall exercise such final decision-making authority in a manner that does not materially
delay, and is consistent with the exercise of Commercially Reasonable Efforts with respect to, the manufacture of Products for
Development and Commercialization. Oncobiologics shall keep MTTR reasonably informed of the manufacturing activities for the Products
(in and outside the Field) by or on behalf of Oncobiologics that are relevant to manufacture of the Products for the Field.

 

9.            Compensation

 

9.1         Retainer
Fees.

 

(a)          Monthly
Retainer Fee. In partial consideration for the Services rendered pursuant to this Agreement and for the assignment of MTTR’s
right, title and interest in Inventions pursuant to this Agreement, Oncobiologics will pay MTTR a monthly retainer fee (“Monthly
Retainer Fee”) in the amount and pursuant to the schedule set forth in the table below (subject to Section 9.3). For
clarity, MTTR shall provide a single invoice per month setting forth in an itemized fashion the costs attributable to work performed
by each Consultant and the aggregate amount payable for such month. Oncobiologics shall pay all undisputed amounts of such invoice
monthly, in arrears, within [***] after receipt of such invoice from MTTR. MTTR shall be solely responsible for all payments to
be made to the Consultants.

 

	Timeframe	Consulting Fee ($)
	(i) Commencing on the Effective Date, until one year after the Effective Date	monthly installments of US$58,333
	(ii) Commencing one year after the Effective Date until the First Commercial Sale of a Product in the Field in the U.S.	monthly installments of $105,208
	(iii) Commencing after First Commercial Sale of a Product in the Field in the U.S.	monthly installments of $170,833

 

(b)          Offset
of Retainer Fee; Reduction in Retainer Fee. The payment of the Monthly Retainer Fee set forth in Section 9.1(a)(iii) shall
be offset against any Profit Share payable to MTTR under Section 9.2. In any Calendar Year (commencing one year after a J code
has been obtained pursuant to the Health Care Procedure Coding System processes for a Product in the U.S. in an Approved Indication,
a “J Code”)) in which the Net Revenues for Products in the U.S. in all Approved Indications is less than [***]
Dollars ([***]), the Monthly Retainer Fee set forth in Section 9.1(a)(iii) shall be reduced by fifty percent (50%).

 

    	17

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

(c)          Reconciliation
of Payments. Within [***] after the end of each Calendar Quarter, Oncobiologics shall conduct a reconciliation and determine
if any reconciliation payment is due from one Party to another for Monthly Retainer Fees paid by Oncobiologics to MTTR in the prior
Calendar Quarter and, if so, the amount of such reconciliation payment period. If any such payment is owed, the applicable Party
shall make such payment to the other Party within [***] after the reconciliation.

 

9.2         Profit
Share.

 

(a)          Profit
Sharing. Subject to Section 9.3, following the First Commercial Sale of any Product in the Field in the U.S., Oncobiologics
shall pay to MTTR an initial percentage of the Net Profits (if any), in accordance with Exhibit C (“Profit Sharing
Percentage”; such profit share, the “Profit Share”); [***]. For clarity, the Profit Sharing Percentage
shall reset to the initial Profit Sharing Percentage on a Calendar Year-by-Calendar Year basis.

 

(b)          Profit
Reports. Within [***] after the end of each [***] following the First Commercial Sale of a Product in the Field in the Territory,
Oncobiologics shall submit to MTTR a report setting forth, with respect to the previous [***]: (i) an itemized calculation
of the Net Profits for each Product, (ii) the amount of each Actual Deductible Cost deducted from such Net Profits, along with
a reasonable basis and explanation for the inclusion of any such costs and expenses that are not specific to use of Products in
the Field, the sum of the aggregate Actual Deductible Costs and the calculation for the Adjusted Deductible Cost (if different
from the Actual Deductible Cost) and (iii) a calculation of the amount of Net Profits, if any (the “Net Profit Report”).
MTTR shall have the right to review and submit any reasonable objection to the calculation of Net Profits within [***] following
its receipt of the Net Profit Report from Oncobiologics. Reasonably prior to the delivery of the first Net Profit Report, the
Parties, along with their respective accountants, shall discuss and agree on financial accounting matters with respect to the
determination and reporting of Net Profits, Actual Deductible Costs and Adjusted Deductible Costs, including any procedures, allocation
mechanisms and reporting requirements. In the event that the Parties are not able to agree on such financial accounting matters
(after good faith discussions of at least [***]), then such disagreement shall be referred to an independent certified public
accounting firm for binding resolution (the cost of which shall be shared by the Parties).

 

(c)          Payments.
Oncobiologics shall pay all undisputed amounts owed to MTTR pursuant to this Section 9.2, if any, at the time of submission of
the Net Profit Report.

 

9.3         Limitations.

 

(a)          The
payment of Monthly Retainer Fees and Net Profits to MTTR shall be contingent upon the performance by each Consultant of the obligations
assigned to such Consultant under the Services Schedule or otherwise under this Agreement in accordance with the terms and conditions
of this Agreement.

 

    	18

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

(b)          In
the event that a Consultant performs fewer hours of work, on an FTE basis (as described in Section 2.2(b)) for a particular Calendar
Quarter than such Consultant should perform pursuant to the agreed-upon time commitment for such Consultant for the relevant Development
Stage of the Product, as set forth in Exhibit B (e.g., if, during a given Calendar Quarter, [***] performs work at a [***]%
FTE level rather than [***]% during Development Stage 1), then Oncobiologics shall have the right to offset future payments owed
to MTTR under Sections 9.1 and 9.2 by the pro rata amount overpaid to MTTR for such Consultant (on the basis of an hourly rate
for such Consultant determined by the anticipated total of Monthly Retainer Fees for the Calendar Quarter, the hours required to
be performed by such Consultant during the applicable Calendar Quarter and such Consultant’s share of the Profit Sharing
Percentage specified in Exhibit C). In the event that there is no possibility of a future payment owed to MTTR, MTTR shall
refund the amount of such overpayment within [***] after receipt of any invoice from Oncobiologics. If a Consultant needs to perform
more hours of work during any Calendar Quarter than agreed upon in Exhibit B, then MTTR will notify Oncobiologics in writing
and shall obtain written approval of Oncobiologics prior to incurring any expenses. In the event that Oncobiologics approves of
such overtime expenses, Oncobiologics shall pay a pro rata amount for such hours (on the basis of an hourly rate determined as
set forth above in this Section 9.3(b)). Notwithstanding anything to the contrary in this Agreement, unless any such additional
hours are pre-approved by Oncobiologics, no Consultant shall, with respect to a given Calendar Quarter, be obligated to perform
more hours of work under this Agreement than as set forth in Exhibit B.

 

9.4         Change
of Control. In the event of (x) a Change of Control of Oncobiologics; (y) an acquisition by a Third Party of Oncobiologics’s
rights to the Product in its entirety, through the sale and/or exclusive out-license by Oncobiologics of all or substantially all
of Oncobiologics’s assets relating to the Product, including all intellectual property owned or controlled by Oncobiologics
that Covers the Product, for use in all fields on a worldwide basis; or (z) an acquisition by a Third Party of Oncobiologics’s
rights to the Product for use in the Field on a worldwide basis, through the sale and/or exclusive out-license by Oncobiologics
of all or substantially all of Oncobiologics’s assets primarily relating to the Product, including all intellectual property
owned or controlled by Oncobiologics that Covers the Product, for use in the Field on a worldwide basis, (each of (x)-(z), an “Acquisition
Event”) the following will apply:

 

(a)          Oncobiologics
will have the right to assign this Agreement in connection with such Acquisition Event in accordance with the terms of Section
16.1;

 

(b)          In
each case of (x), (y) and (z), MTTR shall be entitled to receive, within [***] after Oncobiologics’s receipt thereof, an
amount as follows (such amount as described below, the “Shared Acquisition Consideration”):

 

(1)         in
each case of (x), MTTR shall be entitled to receive an amount equal to [***];

 

(2)         in
each case of (y), MTTR shall be entitled to receive an amount equal to [***];

 

    	19

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

(3)         in
the case of (z), MTTR shall be entitled to receive an amount equal to [***]; and

 

(4)         in
the event that an Acquisition Event occurs prior to the first effective IND filing for the Product in the Field, then in each of
(x), (y) and (z), [***].

 

(c)          Following
such Acquisition Event, [***].

 

(d)         [***],
the terms of this Agreement shall continue as between MTTR and Oncobiologics’s assignee on the same terms as between MTTR
and Oncobiologics, provided that if this Agreement is terminated in its entirety pursuant to Sections 15.5(a) or for any termination
with respect to any Consultant pursuant to Section 15.5(b), then MTTR shall pay to Oncobiologics a percentage of the Shared Acquisition
Consideration received by MTTR that is allocated to the applicable terminated Consultant as follows:

 

	Date of Applicable Termination	Applicable Percentage
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

 

In no event shall Oncobiologics structure
the acquisition consideration received pursuant to subsections (x), (y) or (z) above with the intent to evade payment obligations
owed to MTTR. Any dispute with respect to payments owed to MTTR pursuant to this Section 9.4 [***] shall be resolved by referring
such dispute to an independent valuation firm mutually selected by the Parties; each Party shall provide the valuation firm with
all information and materials in its possession or control as requested by the valuation firm in connection with such valuation.

 

9.5         Payments;
Withholding Tax.

 

(a)          Payments
in Dollars. All payments owed by Oncobiologics under this Agreement shall be made by wire transfer in immediately available
funds to a bank and account designated in writing by MTTR. For clarity, all payments made pursuant to this Agreement shall be in
U.S. dollars.

 

(b)          Withholding
Taxes. If Applicable Law requires withholding of income or other taxes due by Oncobiologics and imposed upon any payments made
by Oncobiologics to MTTR under this Agreement, Oncobiologics shall (i) make such withholding payments as may be required, (ii)
subtract such withholding payments from such payments, (iii) submit appropriate proof of payment of the withholding taxes to MTTR
within a reasonable period of time, and (iv) promptly provide MTTR with all official receipts with respect thereto.

 

    	20

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

(c)          Foreign
Currency Exchange. If, in any Calendar Quarter, Net Profits are received by Oncobiologics in any currency other than U.S. dollars,
such Net Profits shall be converted into U.S. dollars as follows: (A/B), where: “A” = foreign “Net Profits”
in such Calendar Quarter expressed in such foreign currency; and “B” = the applicable foreign exchange conversion rate,
expressed in local currency of the foreign country per U.S. dollar (using, as the applicable foreign exchange rate, the average
of the daily closing rates published in the eastern edition of The Wall Street Journal under the heading “Money Rates,”
or any other mutually agreed upon source, for such Calendar Quarter).

 

(d)          Disputes.
If, following the applicable due date for a payment owed under this Agreement by one Party to the other Party, the Parties disagree
with respect to the calculation of such payment, any undisputed portion shall be paid within [***] of the Parties’ agreement
with respect to such undisputed portion and the remaining, disputed portion shall be paid within [***] after the date on which
the Parties resolve the dispute in accordance with Section 16.4.

 

9.6         Interest
on Late Payments. If either Party does not receive payment of any sum due to it on or before the due date, interest shall thereafter
accrue on the sum due to the such Party until the date of payment at the per annum rate of [***] percent ([***]%) over the then-current
[***] reported in The Wall Street Journal or the maximum rate allowable by Applicable Law, whichever is lower.

 

9.7         Audit
Rights. Each Party shall maintain complete and accurate records in sufficient detail to permit the other Party to verify the
accuracy of the payment obligations hereunder. For clarity, (a) with respect to Oncobiologics as the auditing Party, MTTR shall
maintain records of the number of hours worked by each Consultant during the Term in order for Oncobiologics to verify payment
amounts due under Sections 9.1 and 9.2, and (b) with respect to MTTR as the auditing Party, Oncobiologics shall maintain records
of Actual Deductible Costs, Adjusted Deductible Costs, Net Revenues and Net Profits in order for MTTR to verify the accuracy of
the Net Profit Report furnished by Oncobiologics pursuant to Section 9.2(b) and the amount of Profit Share and other payments due
under this Agreement. All payments and other amounts under this Agreement shall be accounted for in accordance with GAAP. Upon
reasonable prior notice, such records shall be available for examination during regular business hours for a period of [***] to
which they pertain, and not more often than once each Calendar Year, by an independent certified public accountant selected by
the auditing Party and reasonably acceptable to the other Party. Any such auditor shall not disclose Confidential Information of
the Party being audited, except to the extent such disclosure is necessary to verify the accuracy of the payment obligations hereunder.
Any amounts shown to be owed but unpaid shall be paid within [***] from the accountant’s report, plus interest (as set forth
in Section 9.6) from the original due date. Oncobiologics shall bear the full cost of any audit conducted by or on behalf of Oncobiologics
unless such audit discloses an overpayment by Oncobiologics of more than [***] percent ([***]%) of the amount due for the audited
period, in which case MTTR shall bear the full cost of such audit. MTTR shall bear the full cost of any audit conducted by or on
behalf of MTTR unless such audit discloses an underpayment by Oncobiologics of more than [***] percent ([***]%) of the amount due
for the audited period, in which case Oncobiologics shall bear the full cost of such audit.

 

    	21

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

10.         Intellectual
Property

 

10.1       Ownership
of Inventions. Other than with respect to MTTR Regulatory Strategy, MTTR and each of the Consultants hereby irrevocably assigns,
grants and conveys to Oncobiologics all of its right, title and interest now existing or that may exist in the future in and to
any Deliverable, document, development, invention, know-how, design, process, technique, trade secret, or idea, and all intellectual
property rights related thereto, that is created, generated, authored, conceived or reduced to practice by each Consultant, in
the course of performing Services and to the extent related to a Product under this Agreement (the “Inventions”),
including all copyrights, trademarks, patents or other intellectual property rights relating thereto. MTTR agrees that any and
all Inventions shall be and remain the property of Oncobiologics. MTTR will use Commercially Reasonable Efforts to promptly disclose
to Oncobiologics all Inventions, and in any event will promptly disclose to Oncobiologics any material Inventions. MTTR agrees
to execute, at Oncobiologics’s request and expense, all documents and other instruments necessary or desirable to confirm
such assignment with respect to the Inventions. In the event that MTTR does not, for any reason, execute such documents within
a reasonable time of Oncobiologics’s request, MTTR and each of the Consultants hereby irrevocably appoints Oncobiologics
as MTTR’s or such Consultant’s attorney-in-fact solely for the purpose of executing such documents on MTTR’s
(or such Consultant’s) behalf, which appointment is coupled with an interest. MTTR shall not attempt to register any works
created by MTTR pursuant to this Agreement that pertain to Products at the U.S. Copyright Office, the U.S. Patent & Trademark
Office, or any foreign copyright, patent, or trademark registry. MTTR retains no rights in the Inventions and agrees not to challenge
Oncobiologics’s ownership of the rights embodied in the Inventions. MTTR and each of the Consultants further agrees, at Oncobiologics
request and expense, to assist Oncobiologics in every proper way to enforce Oncobiologics’s rights relating to the Inventions
in any and all countries, including, but not limited to, executing, verifying and delivering such documents and performing such
other acts (including appearing as a witness) as Oncobiologics may reasonably request for use in obtaining, perfecting, evidencing,
sustaining and enforcing Oncobiologics’s rights to the Inventions.

 

10.2      Artist’s,
Moral, and Other Rights. If MTTR has any rights, including without limitation “artist’s rights” or “moral
rights,” in any Invention which cannot be assigned (the “Non-Assignable Rights”), MTTR agrees to waive
enforcement worldwide of such rights against Oncobiologics. In the event that MTTR has any such rights that cannot be assigned
or waived, MTTR, on behalf of itself and each of the Consultants, hereby grants to Oncobiologics a royalty-free, paid-up, exclusive,
worldwide, irrevocable, sublicenseable, transferable perpetual license under the Non-Assignable Rights to (a) use, make, have made,
sell, have sold, offer to sell, import, export or otherwise exploit and (b) reproduce, distribute, create derivative works of,
publicly perform and publicly display, the Invention in any medium or format, whether now known or later developed.

 

    	22

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

10.3      License
to MTTR Regulatory Strategy. Effective upon termination or expiration of this Agreement and subject to the terms of Section
15.7, MTTR hereby grants, and agrees to grant, to Oncobiologics a non-exclusive sublicenseable, transferable (in accordance with
Section 16.1) license, under the MTTR Regulatory Strategy, to use, make, have made, sell, have sold, offer for sale, import, export
or otherwise exploit Products in the Field in the Territory. 

 

10.4      No
Conflicts. MTTR represents that [***] is, as of the Effective Date, a full time employee and faculty member of the [***] and
may become, in the future, employed by another academic or research institution (such academic or research institution, an “Institution”).
Nothing in this Agreement shall be construed to conflict with his obligations and duties as such, including his duties (a) to protect
information that is confidential and/or proprietary to [***] or any Institution, (b) to not disclose such protected information
to either MTTR or Oncobiologics, or any Third Party, or (c) to fully comply with [***] or any Institution’s patent policy
and other applicable policies and regulations, including with respect to conflicts of interest and disclosure of this Agreement
to [***] or any Institution as required to comply with such policies and regulations.

 

11.          Representations,
Warranties and Covenants

 

11.1       Mutual
Representations, Warranties and Covenants. Each Party hereby represents, warrants and covenants, as applicable, to the other
Party as follows:

 

(a)          Corporate
Existence. As of the Effective Date, it is a company or corporation duly organized, validly existing, and in good standing
under the Applicable Laws of the jurisdiction in which it is incorporated.

 

(b)          Corporate
Power, Authority and Binding Agreement. As of the Effective Date, (i) it has the corporate power and authority and the legal
right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its
part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; (iii)
this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation
of such Party that is enforceable against it in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization,
moratorium and similar Applicable Laws affecting creditors' rights and remedies generally; and (iv) the execution, delivery and
performance of this Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written,
to which it is a party or by which it may be bound, nor violate any Applicable Laws.

 

(c)          Compliance.

 

(i)          In
the performance of its obligations under this Agreement, each Party shall comply, and shall cause its and its Affiliates’
employees and contractors to comply, with Anti-Corruption Laws and all Applicable Laws. Without limiting the foregoing, each Party,
and its and its Affiliates’ employees and contractors, shall not, in connection with the performance of this Agreement, directly
or indirectly through Third Parties, pay, promise, or offer to pay, or authorize the payment of, any money or give any promise
or offer to give, or authorize the giving of anything of value to any public official or other person or entity for the purpose
of obtaining or retaining business for or with, or directing business to, any person, including, without limitation, either Party.

 

    	23

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

(ii)         Each
Party shall immediately notify the other Party if it has any information or suspicion that there may be a violation of any Applicable
Laws (including Anti-Corruption Laws) in connection with its performance under this Agreement. In the event that either Party has
violated or been suspected of violating any of its obligations, representations, warranties or covenants in this Section 11.1(c),
such Party will take reasonable actions to remedy such breach and to prevent further such breaches from occurring.

 

(iii)        Notwithstanding
the foregoing, each Party will have the right, upon reasonable prior written notice and during the other Party’s regular
business hours, to audit the other Party’s books and records in the event that a suspected violation of any Anti-Corruption
Law needs to be investigated (in such Party’s reasonable, good-faith discretion). Such audit shall be conducted by such Party’s
audit team comprised of qualified auditors who have received anticorruption training. For clarity, a credible finding, after a
reasonable investigation, of any breach of subsections (i) or (ii) above with respect to any Anti-Corruption Law, shall be deemed
a material breach of this Agreement and allow the non-breaching Party to terminate this Agreement in accordance with Section 15.2.

 

11.2      MTTR
Representations and Warranties. MTTR hereby represents, warrants and covenants to Oncobiologics that:

 

(a)          MTTR
has the right and unrestricted ability to assign all Inventions to Oncobiologics in accordance with Article 10, and each of the
Consultants is bound by an enforceable written agreement pursuant to which such Consultant assigns to MTTR all of its right, title
and interest in all Inventions;

 

(b)          MTTR
shall (and shall ensure that each of its Consultants shall) use Commercially Reasonable Efforts, and shall devote the time necessary
on an ongoing basis, to perform the Services in accordance with the Services Schedule and all other terms of this Agreement. MTTR
shall (and shall ensure that each of its Consultants shall) use Commercially Reasonable Efforts to complete the Services in a timely
manner and in accordance with timelines mutually agreed by Oncobiologics and MTTR, including as set forth in the Services Schedule.
The Services, and the results thereof, will be performed with, and be the product of, the professional skill and expertise consistent
with industry standards for the performance of similar services; and

 

(c)          [***].

 

11.3      Oncobiologics
Representations and Warranties.

 

(a)          Oncobiologics
hereby represents, warrants and covenants to MTTR that, as of the Effective Date, there are no Third Party IP Agreements [***].

 

    	24

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

(b)          [***].

 

11.4      No
Other Representations or Warranties. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT,
NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, NON-INFRINGEMENT OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY
OR ON BEHALF OF A PARTY OR ITS AFFILIATE, AND ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE,
ARE HEREBY EXPRESSLY EXCLUDED. For avoidance of doubt, neither Party guarantees any outcome with respect to the activities conducted
under this Agreement.

 

12.          Independent
Contractor Relationship

 

12.1       Independent
Contractor. MTTR (and each Consultant) is an independent contractor and not an employee of the Oncobiologics. Nothing in this
Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship. MTTR
is not authorized to represent that it or any Consultant is an agent, employee, or legal representative of Oncobiologics. MTTR
is not authorized to make any representation, contract, or commitment on behalf of Oncobiologics or incur any liabilities or obligations
of any kind in the name of or on behalf of the Oncobiologics.

 

12.2       Tax
Treatment. MTTR and Oncobiologics agree that Oncobiologics will treat MTTR as an independent contractor for purposes of all
tax laws (local, state and federal) and file forms consistent with that status. MTTR agrees, as an independent contractor, that
neither it nor its employees are entitled to unemployment benefits in the event this Agreement terminates, or workers’ compensation
benefits in the event that MTTR, or any employee of MTTR, is injured in any manner while performing obligations under this Agreement.
MTTR will be solely responsible to pay any and all local, state, and/or federal income, social security and unemployment taxes
for MTTR and its employees. Oncobiologics will not withhold any taxes or prepare W-2 Forms for MTTR, but will provide MTTR with
a Form 1099, if required by Applicable Law. MTTR is solely responsible for, and will timely file all tax returns and payments required
to be filed with, or made to, any Governmental Authority with respect to the performance of Services and receipt of fees under
this Agreement. MTTR is solely responsible for, and must maintain adequate records of, expenses incurred in the course of performing
Services under this Agreement, except as provided herein. No part of MTTR’s compensation will be subject to withholding by
Oncobiologics for the payment of any social security, federal, state or any other employee payroll taxes. Oncobiologics will regularly
report amounts paid to MTTR with the appropriate taxing authorities, as required by Applicable Law.

 

12.3       No
Employee Benefits. MTTR acknowledges and agrees that neither it nor anyone acting on its behalf shall receive any employee
benefits of any kind from Oncobiologics. MTTR (and MTTR’s agents, employees, and subcontractors) is excluded from participating
in any fringe benefit plans or programs as a result of the performance of Services under this Agreement, without regard to MTTR’s
independent contractor status. In addition, MTTR (and MTTR’s agents, employees, and contractors) waives any and all rights,
if any, to participation in any of Oncobiologics’s fringe benefit plans or programs including, but not limited to, health,
sickness, accident or dental coverage, life insurance, disability benefits, severance, accidental death and dismemberment coverage,
unemployment insurance coverage, workers’ compensation coverage, and pension or 401(k) benefit(s) provided by Oncobiologics
to its employees.

 

    	25

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

12.4      Expenses
and Liabilities. MTTR agrees that as an independent contractor, it is solely responsible for all expenses (and profits/losses)
it incurs in connection with the performance of Services. MTTR understands that it will not be reimbursed for any supplies, equipment,
or operating costs, nor will the costs of doing business be defrayed in any way by Oncobiologics except as set forth in this Agreement;
provided however, that MTTR will be reimbursed for reasonable travel and other business expenses in accordance with the
travel policy attached hereto as Exhibit H, to the extent pre-approved by a senior executive of Oncobiologics.

 

13.          Confidentiality

 

13.1      Confidentiality
Obligations. Each of Oncobiologics and MTTR, as a Receiving Party, hereby agrees that, during the Term and for an additional
[***] after termination or expiration of this Agreement, it will (and in the case of MTTR, will ensure that Consultants will):
(a) maintain in confidence such Confidential Information of the Disclosing Party using not less than the efforts such Receiving
Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a reasonable
degree of efforts, (b) not disclose such Confidential Information of the Disclosing Party to any Third Party without the prior
written consent of the Disclosing Party, except for disclosures expressly permitted under this Article 13; and (c) it will not
use any Confidential Information of the Disclosing Party, except as expressly permitted in this Agreement, including in connection
with the exercise of any rights or licenses granted hereunder. Notwithstanding the foregoing, with respect to any Confidential
Information that constitutes a trade secret, the foregoing obligations of confidentiality, non-use and non-disclosure shall continue
for as long as such Confidential Information remains a trade secret. Notwithstanding the definition of Confidential Information
in Section 1.16, Confidential Information of a Receiving Party will not be deemed to include:

 

(a)          any
information that is or becomes generally available to the public other than as a direct or indirect result of the disclosure of
any of such information by the Receiving Party in violation of this Agreement;

 

(b)          any
information that was in the Receiving Party’s possession without obligations of confidentiality with respect thereto prior
to the time it was first made available to the Receiving Party by the Disclosing Party, provided that the source of such information
was not and is not known to the Receiving Party to be bound by any contractual or other obligation of confidentiality to the Disclosing
Party or to any other entity with respect to any of such information;

 

    	26

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

(c)          any
information that becomes available to the Receiving Party on a non-confidential basis from a source other than the Disclosing Party,
provided that such source is not known to the Receiving Party to be bound by any contractual or other obligation of confidentiality
to the Disclosing Party or to any other entity with respect to any of such information; or

 

(d)          any
information that is developed by or on behalf of the Receiving Party independently of the Disclosing Party’s Confidential
Information and without reference to or use of such Confidential Information.

 

13.2      Permitted
Disclosures.

 

(a)          MTTR
hereby agrees, as a Disclosing Party, that Oncobiologics, as a Receiving Party, may disclose MTTR’s Confidential Information:
(i) to any Affiliate, or to its or its Affiliate’s employee, consultant, contractor, subcontractor, agent or sublicensee
on a need-to-know basis in order to enable such person to exercise its rights, or to carry out its responsibilities, under this
Agreement; (ii) on a need-to-know basis to Oncobiologics’s professional, legal or financial advisors; (iii) as reasonably
necessary to any bona fide actual or potential (A) permitted sublicensee of Oncobiologics’s rights hereunder, or (B) investor,
financer or commercial partner of Oncobiologics for purposes of evaluating or carrying out an actual or potential investment, merger,
acquisition, consolidation, share exchange or other similar transaction involving Oncobiologics and such Third Party; (iv) as reasonably
necessary to file, prosecute or maintain patent rights, or to file, prosecute or defend litigation related to patent rights, in
accordance with this Agreement; (v) as reasonably required to obtain Regulatory Approvals; or (vi) as required by Applicable Laws,
including regulations promulgated by court orders, administrative subpoenas and security exchanges; provided, that, in the case
of any disclosure under subsections (iv)-(vi), Oncobiologics shall (x) if practicable, provide MTTR with reasonable advance notice
of and an opportunity to comment on any such required disclosure and (y) if requested by MTTR, cooperate in all reasonable respects
with the MTTR’s efforts to obtain confidential treatment or a protective order with respect to any such disclosure, at MTTR’s
expense. Notwithstanding the foregoing in this Section 13.2(a), Oncobiologics shall not disclose any of MTTR’s Confidential
Information that is MTTR Regulatory Strategy to any Third Party during the Term and for an additional [***] after the termination
or expiration of this Agreement without the prior written consent of MTTR, not to be unreasonably withheld, conditioned or delayed,
provided that Oncobiologics may disclose such MTTR Regulatory Strategy without MTTR’s prior consent (AA) as reasonably required
to be disclosed to regulatory authorities for the purpose of obtaining or maintaining Regulatory Approval of a Product in the Field
in the Territory, in which case the foregoing provisions of subsections (x) and (y) shall apply to such disclosure and (BB) to
a sublicensee of Oncobiologics under the license granted to Oncobiologics under Section 10.3, to the extent reasonably necessary
for such sublicensee to exercise such sublicense.

 

(b)          Oncobiologics
hereby agrees, as a Disclosing Party, that MTTR, as a Receiving Party, may disclose Oncobiologics’s Confidential Information
(i) to any of its or Oncobiologics’s or Oncobiologics’s Affiliates’ consultants, contractors, subcontractors,
agents or sublicensees on a need-to-know basis in order to exercise its rights or carry out its responsibilities under this Agreement,
including the performance of the Services; or (ii) to the extent required by Applicable Laws, including regulations promulgated
by court orders, administrative subpoenas and security exchanges; provided, that, in the case of any such disclosure, MTTR shall
(x) if practicable, provide Oncobiologics with reasonable advance notice of and an opportunity to comment on any such required
disclosure and (y) if requested by Oncobiologics, cooperate in all reasonable respects with the Oncobiologics’s efforts to
obtain confidential treatment or a protective order with respect to any such disclosure, at Oncobiologics’s expense.

 

    	27

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

13.3      Covenants
of Receiving Party. Each of Oncobiologics and MTTR hereby covenants and agrees, as a Receiving Party that any person or entity
who is granted access by such Receiving Party to Confidential Information of the Disclosing Party will, prior to having such access,
be bound by written obligations of confidentiality and non-use no less stringent than the obligations set forth in Section 13.1.
Each Receiving Party will be liable to the other Party for any disclosure or misuse by such person or entity of Confidential Information
of the Disclosing Party.

 

14.         Indemnification;
Insurance; Liability Limitations

 

14.1      Indemnification
by MTTR. MTTR shall defend (solely upon Oncobiologics’s request), indemnify, and hold Oncobiologics and its Affiliates
and their respective officers, directors, employees, and agents (the “Oncobiologics Indemnitees”) harmless from
and against any and all Third Party claims, suits, proceedings, damages, expenses (including court costs and reasonable attorneys’
fees and expenses) and recoveries (collectively, “Claims”) arising out of, based on, or resulting from (a) gross
negligence or willful misconduct of any MTTR Indemnitee in the performance of Services under this Agreement; or (b) the breach
of any of MTTR’s obligations under this Agreement, including MTTR’s representations, warranties or covenants set forth
herein. The foregoing indemnity obligation shall not apply to the extent that (i) the Oncobiologics Indemnitees fail to comply
with the indemnification procedures set forth in Section 14.3 and MTTR’s defense of the relevant Claim is prejudiced by such
failure, or (ii) any Claim arises from, is based on, or results from any activity or occurrence for which Oncobiologics is obligated
to indemnify the MTTR Indemnitees under Section 14.2. Notwithstanding anything to the contrary herein, the foregoing indemnification
obligations of MTTR shall not apply to any Claims that are based on, or resulting from, activities by MTTR Indemnitees that were
expressly authorized in writing by Oncobiologics.

 

14.2      Indemnification
by Oncobiologics. Oncobiologics shall defend, indemnify, and hold MTTR and each of the Consultants (the “MTTR Indemnitees”)
harmless from and against any and all Third Party Claims arising out of, based on, or resulting from (a) the Development, manufacture
or Commercialization of the Product in the Field in the Territory by or on behalf of Oncobiologics or any of its Affiliates; (b)
the breach of any of Oncobiologics’s obligations under this Agreement, including Oncobiologics’s representations, warranties
or covenants set forth herein; or (c) the negligence or willful misconduct of any Oncobiologics Indemnitee. The foregoing indemnity
obligation shall not apply to the extent that (i) the MTTR Indemnitees fail to comply with the indemnification procedures set forth
in Section 14.3 and Oncobiologics’s defense of the relevant Claim is prejudiced by such failure, or (ii) any Claim arises
from, is based on, or results from any activity or occurrence for which MTTR is obligated to indemnify the Oncobiologics Indemnitees
under Section 14.1.

 

    	28

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

14.3      Indemnification
Procedures. The Party claiming indemnity under this Article 14 (the “Indemnified Party”) shall give written
notice to the Party from whom indemnity is being sought (the “Indemnifying Party”) promptly after learning of
such Claim and shall offer control of the defense of such Claim to the Indemnifying Party. The Indemnified Party shall provide
the Indemnifying Party with reasonable assistance, at the Indemnifying Party’s expense, in connection with the defense of
the Claim for which indemnity is being sought. The Indemnified Party may participate in and monitor such defense with counsel of
its own choosing at its sole expense; provided, however, the Indemnifying Party shall have the right to assume and conduct the
defense of the Claim with counsel of its choice. The Indemnifying Party shall not settle any Claim without the prior written consent
of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money. So long as
the Indemnifying Party is actively defending the Claim in good faith, the Indemnified Party shall not settle or compromise any
such Claim without the prior written consent of the Indemnifying Party. If the Indemnifying Party does not assume and conduct the
defense of the Claim as provided above, (a) the Indemnified Party may defend against, consent to the entry of any judgment, or
enter into any settlement with respect to such Claim in any manner the Indemnified Party may deem reasonably appropriate (and the
Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (b) the
Indemnifying Party shall remain responsible to indemnify the Indemnified Party as provided in this Article 14.

 

14.4      Insurance.
Each Party shall procure and maintain insurance, including product liability insurance, adequate to cover its obligations hereunder
and consistent with normal business practices of prudent companies similarly situated; provided that, MTTR shall have no obligation
to obtain product liability insurance. It is understood that such insurance shall not be construed to create a limit of either
Party’s liability with respect to its indemnification obligations under this Article 14. Each Party shall provide the other
Party with written evidence of such insurance upon request. Each Party shall provide the other Party with written notice at least
[***] prior to the cancellation, non-renewal or material change in such insurance.

 

15.          Term
and Termination

 

15.1       Term.
The term of this Agreement is from the Effective Date until the later of (a) (i) for each country in the Major Market Countries
on a country-by-country basis, ten (10) years after the First Commercial Sale of a Product in the Field for an Approved
Indication in such country and (ii) for each country in the Territory outside of the Major Market Countries, ten (10) years
after the First Commercial Sale of a Product in the Field for an Approved Indication in the Territory and (b) on a country-by-country
basis, the expiration of any Regulatory Exclusivity associated with the applicable Product in such country, unless earlier terminated
as provided in this Agreement (the “Term”).

 

    	29

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

15.2       Termination
for Material Breach.

 

(a)          Each
Party shall have the right to terminate this Agreement in its entirety immediately upon written notice to the other Party if the
other Party materially breaches its obligations under this Agreement and, after receiving written notice identifying such material
breach in reasonable detail, fails to cure such material breach within [***] from the date of such notice. For clarity, the failure
of [***] to materially perform his obligations under this Agreement in accordance with the terms herein shall be deemed to be a
material breach of this Agreement by MTTR.

 

(b)          Oncobiologics
shall have the right to terminate this Agreement on a Consultant-by-Consultant basis, immediately upon written notice to MTTR if
(i) the applicable Consultant materially breaches his obligations under this Agreement and, after receiving written notice identifying
such material breach in reasonable detail, fails to cure such material breach within [***] from the date of such notice, or (ii)
the applicable Consultant materially fails to meet the time commitment for such Consultant for the relevant Development Stage of
the Product, as set forth in Exhibit B and determined on a Calendar Quarter basis and fails to materially perform the underlying
Service, as applicable, within [***] of the date of notice thereof.

 

15.3       Termination
Due to Bankruptcy. Either Party may terminate this Agreement if, at any time, the other Party files in any court or agency
pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization
or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, or if the other Party proposes
a written agreement of composition or extension of its debts, or if the other Party is served with an involuntary petition against
it, filed in any insolvency proceeding, and such petition is not dismissed within [***] after the filing thereof, or if the other
Party proposes or becomes a Party to any dissolution or liquidation, or if the other Party makes an assignment for the benefit
of its creditors.

 

15.4       Termination
for Development Failure. Oncobiologics shall have the right to terminate this Agreement immediately, upon [***] prior written
notice to MTTR, in the event that: (i) Oncobiologics fails to achieve any of the milestones set forth for the Development Stages
in Section 4.4 (as such Development Stages may be modified by mutual written agreement of the Parties) in the timeframe outlined
in the initial Development timeline; provided that, Oncobiologics has exercised Commercially Reasonable Efforts to achieve such
milestones, to the extent set forth in Section 4.3(b); or (ii) after the [***] after obtaining the first J Code for a Product in
the U.S., the annual revenue in the U.S. from sales of Products in the Field in the Territory is less than [***] Dollars ($[***]).
For avoidance of doubt, any such failure to achieve such milestones within such timeframes shall not in and of itself provide the
basis for termination by Oncobiologics under Section 15.2 of this Agreement.

 

15.5       Termination
for Failure to Replace Consultant.

 

(a)          If
Oncobiologics does not approve any replacement consultant for [***] pursuant to Section 2.2(c) within [***] of MTTR’s proposal
of such replacement, then, unless the Parties agree otherwise in writing, this Agreement will terminate in its entirety immediately.
For avoidance of doubt, any failure to approve any replacement consultant for [***] pursuant to Section 2.2(c) shall not provide
basis for termination by Oncobiologics under Section 15.2 of this Agreement.

 

    	30

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

(b)          If
Oncobiologics does not approve any replacement consultant for [***] pursuant to Section 2.2(d) within [***] of MTTR’s proposal
of such replacement, then, unless the Parties agree otherwise in writing, this Agreement shall terminate with respect to such Consultant
immediately. For avoidance of doubt, any failure to approve any replacement consultant for the foregoing Consultants pursuant to
Section 2.2(d) shall not provide basis for termination by Oncobiologics under Section 15.2 of this Agreement.

 

15.6       [***].

 

15.7       Effects
of Termination.

 

(a)          Upon
any termination or expiration of this Agreement in its entirety, each Party shall return to the other Party, or at such other Party’s
option, destroy, all copies of such Confidential Information then in such Party’s possession; provided that, each Party may
retain a copy of the other Party’s Confidential Information for legal archival purposes; provided, however, that with respect
to a termination by Oncobiologics pursuant to Section 15.2(b), the foregoing shall apply only with respect to such terminated Consultant.

 

(b)          Upon
any termination or expiration of this Agreement in its entirety, MTTR shall promptly furnish to Oncobiologics all Inventions in
MTTR’s possession as of the date of termination or expiration. Oncobiologics shall not perform any additional Services or
incur any additional expenses with respect to this Agreement without Oncobiologics’s prior written approval; provided, however,
that with respect to a termination by Oncobiologics pursuant to Section 15.2(b), the foregoing shall apply only with respect to
such terminated Consultant.

 

(c)          [***]

 

(d)          [***]

 

(e)          With
respect to a termination of this Agreement with respect to a Consultant by Oncobiologics pursuant to Section 15.2(b) or as set
forth in Section 15.5(b), the Monthly Retainer Fee and Profit Sharing Percentage shall be reduced in accordance with the applicable
Consultant’s share of the Profit Sharing Percentage specified in Exhibit C as of the date of delivery of written notice
of termination.

 

15.8       Survival.
Termination or expiration of this Agreement shall not affect rights or obligations of the Parties under this Agreement that have
accrued prior to the date of termination or expiration. Such termination or expiration shall not relieve a Party from obligations
that are expressly indicated to survive the termination or expiration of this Agreement. Notwithstanding anything to the contrary,
the following provisions shall survive any expiration or termination of this Agreement: [***], together with any other provisions needed to effectuate the
intent of the foregoing. If this Agreement is terminated with respect to a Consultant but not in its entirety, then the foregoing
provisions of this Agreement shall remain in effect with respect to the terminated Consultant (to the extent such provisions would
survive and apply in the event this Agreement expires or is terminated in its entirety), and all provisions not surviving in accordance
with the foregoing to the extent applicable to the terminated Consultant shall terminate upon termination of this Agreement and
be of no further force and effect (and, for purposes of clarity, all provisions of this Agreement shall remain in effect with
respect to the remaining Consultants that are not terminated).

 

    	31

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

16.          Miscellaneous

 

16.1       Successors
and Assigns. MTTR may not assign, transfer or delegate this Agreement or any of its obligations hereunder without Oncobiologics’s
prior written consent (which may be withheld, conditioned or delayed, in Oncobiologics’s sole discretion). Oncobiologics
may not assign, transfer or delegate this Agreement or any of its obligations hereunder without MTTR’s prior written consent
(which may be withheld, conditioned or delayed, in MTTR’s sole discretion), except that Oncobiologics may assign this Agreement
without MTTR’s prior written consent (a) to an Affiliate of Oncobiologics, so long as Oncobiologics remains responsible for
the activities of such Affiliate and all of such Affiliate’s obligations under this Agreement, (b) to a successor of Oncobiologics
in the event of a Change of Control of Oncobiologics or (c) to an exclusive sublicensee of all of Oncobiologics’s rights
to the Products for use (i) in the Field in the Territory or (ii) in all fields on a worldwide basis.

 

16.2       Notices.
Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given
as indicated: (a) by overnight courier upon written verification of receipt; or (b) by email or facsimile transmission with confirmation
of receipt of transmission. Notice shall be sent to the addresses set forth below or such other address as either Party may specify
in writing.

 

If to Oncobiologics:

7 Clarke Drive

Cranbury, New Jersey 08512

Attn: [***]

Tel: [***]

Email: [***]

Facsimile: [***]

 

If to MTTR:

[***]

Attn: [***]

Tel: [***]

Email: [***]

Facsimile: [***]

 

16.3       Governing
Law. This Agreement shall be governed in all respects by the laws of the State of Delaware, without regard to the application
of principles of conflicts of law.

 

    	32

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

16.4       Arbitration.
Either Party may submit any dispute arising hereunder to binding arbitration pursuant to the [***]. The arbitration shall be conducted
in [***]. In any arbitration under this Section 16.4, the arbitrator and the Parties shall use their best efforts to resolve such
dispute within [***] after the selection of the arbitrator, or as soon thereafter as is practicable. The decision of the arbitrator
or shall be final and binding upon the Parties and shall be enforceable by any court of competent jurisdiction. By agreeing to
arbitration, the Parties do not intend to deprive any competent court of such court’s jurisdiction to issue a pre-arbitral
injunction, pre-arbitral attachment or other order in aid of the arbitration proceedings and the enforcement of any award or judgment.
Without prejudice to such provisional remedies in aid of arbitration as may be available under the jurisdiction of a national court,
the arbitrator shall have full authority to grant provisional remedies and to award damages for failure of any Party to respect
the court of arbitration’s order to that effect. The expenses of any arbitration shall be borne equally by the Parties, except
as otherwise allocated by the arbitrator. Each Party shall bear the expenses of its counsel and other experts in connection with
any arbitration proceedings.

 

16.5       Severability.
Should any provisions of this Agreement be held by a court of law to be illegal, invalid or unenforceable, the legality, validity
and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby.

 

16.6       Waiver.
The waiver by either Party of a breach of any provision of this Agreement by the other Party shall not operate or be construed
as a waiver of any other or subsequent breach by such other Party.

 

16.7       Entire
Agreement. This Agreement constitutes the entire understanding of the Parties relating to the subject matter and supersedes
any previous oral or written communications, representations, understanding, or agreement between the Parties concerning such subject
matter, including the Confidentiality Agreement. This Agreement may not be changed, modified, supplemented or amended except by
express written agreement signed by an authorized representative of each of the Parties.

 

16.8      Construction.
Except where the context otherwise requires, (a) wherever used, the singular shall include the plural, the plural shall include
the singular; (b) the terms “including,” “include,” “includes” or “e.g.,” shall
be deemed to mean “including, without limitation”; (c) the word “or” has the inclusive meaning that is
typically associated with the phrase “and/or”; and (d) the word “will” means “shall”; (f) “Dollar”
or “$” means U.S. Dollars. Each Party represents that it has been represented by legal counsel in connection with this
Agreement and acknowledges that it has participated in the drafting hereof.

 

16.9       Equitable
Relief. Each Party acknowledges that its breach of Article 13 (and in the case of MTTR, its breach of Section 5.1) may cause
irreparable harm to the other Party, which cannot be reasonably or adequately compensated in damages in an action at law. By reasons
thereof, each Party agrees that the other Party shall be entitled, in addition to any other remedies it may have under this Agreement
or otherwise, to seek preliminary and permanent injunctive and other equitable relief to prevent or curtail any actual or threatened
breach of such obligations.

 

    	33

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

16.10    Force
Majeure. A Party shall be excused from the performance of its obligations under this Agreement to the extent that such performance
is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse
shall be continued so long as the condition constituting force majeure continues and the nonperforming Party takes reasonable efforts
to remove the condition. For purposes of this Agreement, force majeure shall include conditions beyond the reasonable control of
the applicable Party, including an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, failure
or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm
or like catastrophe, and failure of plant or machinery. Notwithstanding the foregoing, a Party shall not be excused from making
payments owed hereunder because of a force majeure affecting such Party. If a force majeure persists for more than [***], then
the Parties will discuss in good faith the modification of the Parties’ obligations under this Agreement in order to mitigate
the delays caused by such force majeure. If a force majeure persists for more than [***], then either Party shall have the right
to terminate this Agreement in its entirety upon written notice to the other Party.

 

16.11    Limitation
of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT
DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.
NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 16.11 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS
OR OBLIGATIONS OF ANY PARTY UNDER SECTION 14.1 OR 14.2, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS
IN ARTICLE 13 OR ITS OBLIGATIONS UNDER SECTIONS 5.1 AND 5.2 OR THAT RESULT FROM THE INTENTIONAL BREACH OF THIS AGREEMENT.

 

    	34

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

In
Witness Whereof, the Parties have executed this Agreement as of the date first written above.

 

	Oncobiologics, Inc.	 	MTTR, LLC
	 	 	 	 	 
	By:	/s/ Pankaj Mohan	 	By:	/s/ [***]
	Pankaj Mohan, Ph.D.	 	Name: [***]
	Chairman and CEO	 	Title: [***]

 

    	35

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

EXHIBIT A

Services Schedule

 

Description of Services (including
applicable Deliverables and timelines for completion)

 

The following activities and deliverables with respect
to the Product in the Field in the Territory:

[***]

 

	AGREED TO:
	MTTR, LLC
	 	 	Date: 	 
	AGREED TO:
	Oncobiologics, Inc.
	 	 	Date: 	 

 

 

    	36

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

EXHIBIT B

Consultant Expertise & Time Commitments

 

		A.	Consultant Expertise

 

		(1)	[***]

 

		(2)	[***]

 

		(3)	Mr. Dagnon is a senior executive with regulatory, operations,
quality and compliance experience.

 

		(4)	[***]

 

		B.	Consultant Time Commitments (as a percentage of FTE and
pro-rated based on the actual number of days during the applicable Development Stage)

 

		(1)	Development Stage 1:

 

		(a)	[***]

		(b)	[***]

		(c)	Mr. Dagnon – 25%

		(d)	[***]

 

		(2)	Development Stage 2:

 

		(a)	[***]

		(b)	[***]

		(c)	Mr. Dagnon – 75%

		(d)	[***]

 

		(3)	Development Stage 3:

 

		(a)	[***]

		(b)	[***]

		(c)	Mr. Dagnon – 100%

		(d)	[***]

 

		(4)	Development Stage 4:

 

		(a)	[***]

		(b)	[***]

		(c)	Mr. Dagnon – 100%

		(d)	[***]

 

    	37

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

EXHIBIT
C

Profit Sharing Percentage

 

 

Subject to the terms and conditions of
this Agreement, including the adjustment pursuant to Section 9.2(a), Oncobiologics shall pay MTTR [***] of Net Profits.

 

[***] share of such amount paid to MTTR shall be [***]
and each of the other three (3) Consultants share of such amount shall be [***].

 

    	38

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

EXHIBIT D

Development Costs

  

[***]

 

    	39

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

EXHIBIT E

Initial Development Timelines

 

[***]

 

    	40

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

EXHIBIT F

Primary End Points

 

[***]

 

    	41

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

EXHIBIT G

Oncobiologics’s Initial JSC Members

 

[***]

 

MTTR’s Initial JSC Members

 

[***]

 

MTTR’s Initial Alternate JSC Members

 

[***]

 

    	42

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

EXHIBIT H

Travel Policy

 

[***]

 

    	43

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

 

EXHIBIT I

[***]

[***]

 

    	44

    	[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    

 

MTTR,
LLC

[***]

Attention: [***]

Email: [***]

 

March
2, 2018

 

Oncobiologics, Inc.

7 Clarke Drive

Cranbury, NJ 08512

Attention: Pankaj Mohan,
Ph.D.

Email: [***]

 

		Re:	Monthly retainer payment schedule adjustment, additional one-time fee, and MTTR consultant time
commitment

 

Dear Pankaj:

 

This letter is to confirm
our understanding with respect to certain changes to the Strategic Partnership Agreement between Oncobiologics, Inc. (“Oncobiologics”)
and MTTR, LLC (“MTTR”) dated February 15, 2018 (the “Agreement”). Such changes are as set
forth below:

 

1.       The
table set forth in Section 9.1(a) of the Agreement is not changed in terms of monthly retainer installments but hereby is amended
in terms of timing by the following table:

 

	Timeframe	 	Consulting
    Fee ($) 

    (prorated as needed)
	(i) Commencing on the Effective Date until December 31, 2018	 	monthly installments of US$58,333
	(ii) Commencing January 1, 2019 until First Commercial Sale of a Product in the Field in the U.S.	 	monthly installments of $105,208
	(iii) Commencing after First Commercial Sale of a Product in the Field in the U.S.	 	monthly installments of $170,833

 

2.       In
consideration of [***], as reflected by the [***] within [***] (as compared to [***] listed in Exhibit E), Oncobiologics agrees
to pay a one-time [***] fee of $268,553 to MTTR by September 11, 2020. The amount paid by Oncobiologics to MTTR pursuant to this
Paragraph 2 as well as all and any retainer payments shall be excluded from the determination of Development Costs under Section
4.3(b) of the Agreement.

 

    	 	45	 

     

    

 

3.       Subsection
B of Exhibit B is hereby also amended as follows:

 

		B.	Consultant Time Commitments (as a percentage of FTE and pro-rated based on the actual number of days during the applicable
period)

 

		(1)	Effective Date until December 31, 2018:

		(a)	[***]

		(b)	[***]

		(c)	Mr. Dagnon – 25%

		(d)	[***]

 

		(2)	January 1, 2019 until December 31, 2019:

		(a)	[***]

		(b)	[***]

		(c)	Mr. Dagnon – 70%

		(d)	[***]

 

		(3)	January 1, 2020 until First Commercial Sale of a Product
in the Field in the U.S.:

		(a)	[***]

		(b)	[***]

		(c)	Mr. Dagnon – 70%

		(d)	[***]

 

		(4)	After First Commercial Sale of a Product in the Field
in the U.S.:

		(a)	[***]

		(b)	[***]

		(c)	Mr. Dagnon – 100%

		(d)	[***]

 

Please confirm Oncobiologics’s
agreement with the changes as set forth in this letter by signing this letter and returning a countersigned copy to me at [***].
I look forward to receiving your agreement, and thank you for your assistance in this matter.

 

	 	Sincerely,
	 	MTTR, LLC
	 	 
	 	By:	/s/ [***]
	 	[***]

 

	Agreed by Oncobiologics, Inc.:	 
	 	 
	By: 	/s/ Pankaj Mohan, Ph.D.	 
	Name: 	Pankaj Mohan, Ph.D.	 
	Title:  	 Chairman and CEO	 

 

    	 	46Exhibit 10.26

 

LEASE TERMINATION AGREEMENT

 

THIS LEASE TERMINATION AGREEMENT is
made as of the 28th day of August, 2018, by and between CEDAR BROOK EAST CORPORATE CENTER, LP, a New Jersey limited partnership,
whose address is 4A Cedar Brook Drive, Cranbury, New Jersey 08512 (hereinafter referred to as "Landlord");
and ONCOBIOLOGICS, INC., a Delaware corporation, whose address is 7 Clarke Drive, Cranbury, New Jersey 08512 (hereinafter
referred to as "Tenant").

 

RECITALS:

 

A.            Landlord
and Tenant have entered into that certain Lease for certain real property and improvements located at 9 Cedar Brook Drive, Cranbury,
New Jersey, constituting a portion of the office/industrial park known as Cedar Brook Corporate Center, dated August 31, 2015 (the
"Lease")·

 

B.            Landlord
and Tenant have agreed to terminate the Lease subject to the terms and conditions set forth herein.

 

NOW, THEREFORE,
in consideration of the foregoing premises and the mutual covenants and conditions herein contained and for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Landlord and Tenant hereby agree as follows:

 

1.           Recitals.
The Recitals set forth above are incorporated and shall be deemed a part of this Agreement.

 

2.           Defined
Terms. All defined terms not defined herein shall have the same meaning herein as set forth in the Lease.

 

3.           Termination.
Landlord and Tenant agree that the Lease is hereby terminated as of September 1, 2018 ("Lease Termination Date")
and, as of such date, Tenant shall have no further rights to occupancy or possession of the Demised Premises under the Lease and,
except as expressly provided in this Agreement, each party hereby releases each other, their respective successors and assigns
of and from any and all claims, damages, obligations, liabilities, actions and causes of action, of every kind and nature whatsoever
arising out of the Lease from and after the Lease Termination Date. Except as expressly set forth herein, from and after the Lease
Termination Date, neither Landlord nor Tenant shall have any further rights or obligations under the Lease. Landlord and Tenant
shall execute a separate certificate (the “Lease Termination Certificate”, attached hereto and made a
part hereof as Exhibit A) evidencing the termination of the Lease which shall be subject to the terms set forth herein.

 

4.           Representations.
Landlord and Tenant each represent and warrant to the other that (i) Tenant has vacated the Demised Premises in full compliance
with all the terms and provisions of the Lease, and (ii) each has the full power and authority to enter into this Agreement and
to perform its obligations hereunder without the consent or approval of any other person or entity which has not already been obtained.
Tenant represents and warrants that it has not assigned the Lease or sublet its interest in the Lease.

 

5.           Releases.

 

(a)       Effective
as of the Lease Termination Date, Landlord does hereby remise, release and forever discharge Tenant, its successors and assigns,
from all obligations and liability under the Lease except as expressly set forth in this Agreement and Landlord hereby agrees that,
as of the Lease Termination Date, the Lease is hereby cancelled, null and void and of no further force or effect.

 

    			 

     

    

 

 

(b)       Effective
as of the Lease Termination Date, Tenant does hereby remise, release and forever discharge Landlord, its successors and assigns,
from all obligations and liability under the Lease, and Tenant hereby agrees that, as of the Lease Termination Date, the Lease
is hereby cancelled, null and void and of no further force or effect.

 

The foregoing releases shall not affect the terms and provisions
of this Agreement which shall remain in full force and effect in accordance with the terms set forth herein.

 

6.           Consideration
Payable to Landlord for Lease Termination. In consideration of and as a condition to Landlord's agreement to terminate
the Lease and all obligations thereunder other than as provided herein, Tenant shall, and covenants and agrees to, pay to Landlord:
(i) upon execution of this Lease Termination Agreement, the sum of Two Hundred Eighty Seven Thousand Six Hundred Fifteen Dollars
($287,615.00), constituting the unamortized balance of the broker fee paid by the Landlord for the Lease, as indicated on Exhibit
B attached hereto and made a part hereof, (ii) on a monthly basis, commencing on September 1, 2018 and on the first day of each
of the twenty-nine (29) months thereafter, the sum of Fifty Thousand Dollars ($50,000) (the "Monthly Lease Termination
Payments") and, together with the thirtieth (30th) Monthly Lease Termination Payment, and, in any event, on or before
February 1, 2021, the sum of Four Million Dollars ($4,000,000.00) (the "Final Lease Termination Payment").
Landlord and Tenant agree that the amount of the security deposit held by the Landlord under the Lease is One Hundred Seventy Four
Thousand Two Hundred Fifty Dollars ($174,250.00), and that such amount shall be retained by the Landlord as payment of the seventh,
eighth and ninth Monthly Lease Termination Payments and partial payment of the tenth Monthly Lease Termination Payment (leaving
a balance of $25,750). Notwithstanding the foregoing, Tenant shall have the right, at any time, to pay the Final Lease Termination
Payment, whereupon Tenant's obligation to make any further Monthly Lease Termination Payments shall terminate. All payments hereunder
shall be paid to Landlord by wire transfer of immediately available funds in accordance with Landlord's wire transfer instructions.
There shall be no further payments or adjustments between the parties. In the event Tenant shall fail to pay any Monthly Lease
Termination Payment, or the Final Lease Termination Payment, within ten (10) days of receiving notice from Landlord of such failure
to make any such payment when due, Landlord shall have the right, in addition to all other rights available at law or in equity
for such breach, to accelerate the remaining balance of payments hereunder, whereupon the same shall immediately become due and
payable in full.

 

7.           No
Subsequent Adjustments. Landlord and Tenant acknowledge that Tenant's payment of the Monthly Lease Termination Payments
and the Final Lease Termination Fee shall be made without offset or claim and the same shall satisfy all of Tenant's obligations
to pay Fixed Annual Rent, Additional Rent and all other charges accrued and outstanding for the period up to and including the
Expiration Date.

 

8.           Captions.
The captions preceding the various paragraphs of this Agreement have been inserted solely for convenience of reference and shall
not be used in construing this Agreement.

 

9.           Choice
of Law. This Agreement shall be governed by the laws of the State of New Jersey.

 

    			 

     

    

 

10.         Successors
and Assigns. This Agreement shall be binding upon the parties hereto, their successors and permitted assigns, and may not
be altered, amended, terminated or modified except by written instrument executed by the parties hereto.

 

11.        Counterparts.
This Agreement may be executed in several counterparts, which shall constitute one and the same instrument. Execution of this Agreement
by PDF or facsimile shall bind the parties.

 

12.        Construction.
This Termination Agreement has been drafted by Landlord as a matter of convenience and shall not, on such account, be interpreted
against or for either party, it being understood that each of the parties has had an opportunity to submit revisions to the text
hereof.

 

[SIGNATURES APPEAR ON THE FOLLOWING PAGE]

 

    			 

     

    

 

IN WITNESS WHEREOF the parties have hereunto
set their hands and seal the day and year first above written.

 

	 	Cedar Brook East Corporate Center, LP, Landlord
	 	 	 
	 	By:	/s/ Joe Stern
	 	 	Name: Joe Stern
	 	 	Title:
	 	 	 
		OncoBiologics, Inc., Tenant
	 	 	 
	 	By:	/s/ Lawrence A. Kenyon
	 	 	Name:  Lawrence A. Kenyon
	 	 	Title:  President and CEO

 

    			 

     

    

 

EXHIBIT A

 

LEASE TERMINATION CERTIFICATE

 

THIS LEASE TERMINATION
CERTIFICATE is made as of the 28th day of August, 2018, by and between CEDAR BROOK EAST CORPORATE CENTER, LP, a New Jersey
limited partnership, whose address is 4A Cedar Brook Drive, Cranbury, New Jersey 08512 (hereinafter referred to as "Landlord");
and ONCOBIOLOGICS, INC., a Delaware corporation, whose address is 7 Clarke Drive, Cranbury, New Jersey 08512 (hereinafter referred
to as "Tenant").

 

Landlord and Tenant have
entered into that certain Lease for certain real property and improvements located at 9 Cedar Brook Drive, Cranbury, New Jersey,
(the “Demised Premises”) constituting a portion of the office/industrial park known as Cedar Brook Corporate
Center, dated August 31, 2015 (the "Lease")·

 

NOW, THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree
that, pursuant to the Lease Termination Agreement executed simultaneously herewith, the Lease is hereby terminated as of September
1, 2018 (the “Lease Termination Date”) and, as of such date, Tenant shall have no further rights to occupancy
or possession of the Demised Premises under the Lease and, except as provided in the Lease Termination Agreement, the parties to
the Lease release each other, their respective successors and assigns of and from any and all claims, damages, obligations, liabilities,
actions and causes of action, of every kind and nature whatsoever arising out of the Lease from and after the Lease Termination
Date.

 

This Certificate may be
executed in several PDF counterparts, which shall constitute one and the same instrument.

 

[SIGNATURES APPEAR ON THE FOLLOWING PAGE]

 

    			 

     

    

 

IN WITNESS WHEREOF the parties have hereunto
set their hands and seal the day and year first above written.

 

	 	Cedar Brook East Corporate Center, LP, Landlord
	 	 
	 	By:	/s/ Joe Stern
	 	 	Name: Joe Stern
	 	 	Title:
	 	 	 
	 	OncoBiologics, Inc., Tenant
	 	 	 
	 	By:	/s/ Lawrence A. Kenyon
	 	 	Name:  Lawrence A. Kenyon
	 	 	Title:  President and CEO

 

    			 

     

    

 

EXHIBIT B

 

UNAMORTIZED COMMISSION FROM 9/1/2018

 

	9/1/18-2/28/21	 	 	 
	30 months’ rent: month is	 	$	58,083.33	 
	Rent for 30 months:	 	$	1,742,500	 
	3/1/21-2/28/26	 	 	 	 
	60 months’ rent: per month is	 	$	66,830	 
	Rent for 60 months:	 	$	4,009,800	 
	Total rent:	 	$	5,752,300	 
	Commission at 5%	 	$	287,615.00

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]